Review

Stroke and Bleeding Risk Assessments in Patients with Atrial Fibrillation:

Concepts and Controversies

Wern Yew Ding1, MRCP

Stephanie Harrison1, PhD

Dhiraj Gupta1, MD

Gregory Y. H. Lip1,2, MD\*

Deirdre A. Lane1,2, PhD\*

1Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom; 2Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark

[\*joint senior authors]

**Corresponding Author:**

Prof Gregory Y H Lip gregory.lip@liverpool.ac.uk

Full mailing address University of Liverpool

William Henry Duncan Building

6 West Derby Street

Liverpool, L7 8TX

Telephone number 0151 794 9020

Word count 7,243

Key words Stroke; bleeding; risk factors; risk assessment; atrial fibrillation

# Abstract

Risk assessments are an important element in the management of patients with atrial fibrillation (AF). In this review, we aim to discuss the concepts and controversies surrounding the various risk factors for stroke and bleeding in AF. Indeed, there are a variety of clinical, electrical, biological and genetic markers to guide stroke and bleeding risk assessments in AF. The more common factors have been used to formulate risk stratification scores. Some risk factors have shown promise, but others remain less well-defined. Our aim is to discuss concepts and controversies surrounding current evidence of risk factors for stroke and bleeding assessments in AF.

# Introduction

Risk assessments are an important element in clinical practice. Therefore, it is crucial to understand the evidence supporting the individual risk factors to help guide management of patients with complex conditions such as atrial fibrillation (AF). Atrial fibrillation is the most common sustained cardiac arrhythmia. In 2010, the estimated global prevalence of AF was 33.5 million with approximately 5 million new cases identified (1). The condition is associated with a greater risk of stroke and heart failure, reduced quality of life, and a 2-fold increased mortality (1–5). In addition, it poses a significant healthcare economic burden. Conservative estimates in the United Kingdom found that AF was associated with a direct annual cost of £459 million, based on an estimated 0.5 million affected patients (6). However, as AF has detrimental effects on many other comorbidities, the total cost of AF is expected to be significantly higher. A study in the United States on AF-related cost estimates this to be as high as $26 billion per year (7). Perhaps most worryingly, the incidence and prevalence of AF is increasing worldwide (8,9). Between 5.6 to 15.9 million people in the United States are projected to have AF by 2050 (10,11) and 17.9 million people in Europe by 2060 (12).

Given the higher stroke risk associated with AF, an integrated approach in the management of patients with AF must include accurate stroke risk stratification. Patients who are *not* identified as ‘low risk’ should then be offered anticoagulation therapy to reduce their risk of stroke. However, the use of anticoagulation carries an increased risk of bleeding. Most bleeding events are multifactorial in nature and some may have devastating clinical consequences. Therefore, it is important to consider and treat any modifiable bleeding risk factors prior to commencing anticoagulation.

Overall, stroke and bleeding risk assessments in AF are complex with ever emerging evidence. Therefore, it can be challenging for clinicians to stay up to date with the most recent literature and appreciate the interplay of the various factors involved. This article is not an exhaustive systematic review of the vast literature on this topic. Our aim is to discuss concepts and controversies surrounding current evidence of risk factors for stroke and bleeding assessments in AF.

# Stroke risk assessment

In general, AF is associated with a five-fold increased risk of stroke (13). Furthermore, stroke outcomes are more severe in the presence of AF, as determined by clinical or radiological assessment (14,15). Various factors based on clinical, electrical, biological and genetic markers have been shown to predict stroke risk in AF (**Table 1Table 1**). Using a culmination of different risk factors, predominantly clinical, various authors have developed a total of at least 15 risk scores to assist stroke risk stratification in AF (16–19).

At present, the majority of clinical guidelines recommend the use of CHA2DS2-VASc score to aid decision on anticoagulation therapy (20–24). This tool was refined from the original 2006 Birmingham/’National Institute for Health and Care Excellence’ stroke risk schema with a specific focus on optimal identification of low-risk individuals and subsequently validated in several large AF cohorts (18,25). In general, higher scores are associated with an increased annual risk of ischaemic stroke. Males with a score of 0 and females with a score of 1 are considered at ‘low-risk’ of stroke, with event rates <1% per year. Current recommendations support consideration of anticoagulation therapy in all other patients where there is sufficient stroke risk to justify the hazards of anticoagulation.

Older studies have suggested that so-called ‘lone AF’, contributes to an annual stroke risk of 1% (26). However, more contemporary studies have found that stroke rate in such low-risk patients is <1% per year, as defined by age <65 years and the absence of any established stroke risk factors (27).

## Clinical markers

Atrial fibrillation is a multi-systemic disorder that often occurs alongside other comorbidities. Many of these co-morbidities are risk factors for incident AF and may also increase the risk of subsequent complications. Pooled analysis from five randomised controlled trials (RCTs) demonstrated that a history of stroke or transient ischaemic attack (TIA), increasing age, hypertension, diabetes mellitus and congestive heart failure were individual risk factors for stroke in AF (26). A more recent systematic review of seven studies which included over 12,000 patients found similar results, although there was inconclusive evidence to support congestive heart failure and coronary artery disease as risk factors (28). Prior stroke or TIA was the most powerful predictor of further stroke events, contributing to an annual risk of >5%. Increasing age (per decade), hypertension and diabetes mellitus were each associated with a 1.5 to two-fold greater stroke risk. In a separate study, Olesen *et al.* demonstrated that the presence of heart failure, previous stroke and vascular disease were independent predictors of stroke or thromboembolism among AF patients aged under 65 years (29). A Swedish cohort study found that peripheral artery disease, vascular disease, prior myocardial infarction, female sex, prior embolism, intra-cranial haemorrhage (ICH), hypertension and diabetes mellitus were associated with additional thromboembolic events (25). The mechanism by which the conditions above influence stroke risk in AF is likely multifactorial and partly related to its influence on progression of the disease through atrial substrate remodelling. Furthermore, many of these conditions are pro-thrombotic by nature.

Among non-anticoagulated patients in the ATRIA study, females had a 60% higher risk of thromboembolism compared to males (30). Similar findings were shown in a cohort of anticoagulated patients where females had a two-fold higher risk of ischaemic stroke (31). However, a subsequent population-based cohort study of 147,622 patients with AF failed to reproduce these results (32). A study by Nielsen *et al.* demonstrated similar rates of thromboembolism for both sexes among AF patients deemed at lowest risk (33). Excess risk in females were only evident for those with two or more non-sex-related stroke risk factors. Therefore, although female sex should remain an important component for stroke risk assessment in AF, it should be considered in the context of other risk factors (‘risk modifier’).

## Electrical markers

Several electrical markers relating to AF have been described to predict stroke risk (**Table 2**). The impact of AF type (paroxysmal or sustained) on stroke risk remains controversial with earlier studies reporting a similar risk of stroke and systemic thromboembolism in paroxysmal AF compared to sustained or permanent AF (34–36). These results were supported by two independent systematic reviews which included a total of nine relevant studies (28,37). However, a third systematic review of 12 studies which included just under 100,000 patients demonstrated that non-paroxysmal AF was associated with a hazard ratio of 1.38 (95% confidence interval (CI), 1.17 - 1.57) for thromboembolism compared to paroxysmal AF, after multivariable adjustment (38). The finding was reinforced by results from the ENGAGE AF-TIMI 48 trial which showed fewer thromboembolic events among patients with paroxysmal AF compared to those with sustained AF (39). There was no difference in thromboembolic risk between patients with persistent and permanent AF in the study. Given the current evidence, it would appear that sustained AF is likely to be associated with a higher stroke risk overall. However, it remains unclear whether the increased risk is due to shared underlying mechanisms of the disease or if the burden of AF itself is directly implicated.

The method(s) by which AF is identified has evolved significantly over the past decade. While AF was previously detected predominantly using standard 12-lead electrocardiogram (ECG), the increased use of implantable devices has contributed to a rise in ‘device-detected AF’. The rise of device-detected AF has also led to new terms such as ‘atrial high-rate episodes’ (AHRE) and ‘subclinical atrial tachyarrhythmias’ - both of which are sometimes used interchangeably with AF. These changes have sparked important questions such as “what duration of AF is required for diagnosis?”, “what is the threshold of AF burden where it becomes clinically important?” and “what is the threshold of AF burden at which anticoagulation will provide a net benefit?”. While many of these questions remain unanswered, there are some evidence to shed light on the matter. Several studies have investigated the threshold of AF burden associated with a negative clinical outcome. The MOST study found that patients with at least one AHRE (defined as an atrial rate >220 bpm) lasting ≥5 minutes had a two-fold risk of stroke or mortality, and six-fold risk of developing AF compared to patients without AHRE (40). The ASSERT study similarly found that subclinical atrial tachyarrhythmias (defined as an atrial rate >190 bpm) lasting >6 minutes was associated with an increased risk of incident AF, and ischaemic stroke or systemic embolism (41). In contrast, Capucci *et al.* performed a study using pre-specified AF durations in which the authors demonstrated that AF duration of >5 minutes was not associated with thromboembolic events unlike episodes >24 hours which were independently associated with thromboembolic events (42). A potential explanation for the differences observed in this study may be related to the fact that a significant proportion of patients had short episodes of AF (about 80%). Pooled analysis of five prospective studies that included 10,016 patients with implantable devices found that AF burden was an independent predictor of ischaemic stroke (43). In this study, patients with one hour of AF per day were found to be at highest risk. Among patients with paroxysmal AF, authors of the KP-RHYTHM study reported a three-fold increased risk of thromboembolism in those with the highest tertile of AF burden (≥11.4%) compared to the lower two tertiles, after adjusting for either ATRIA or CHA2DS2-VASc score (44). A further study in patients with dual-chamber pacemakers also confirmed that patients with thromboembolism had higher AF burden (45). Overall, AF burden may reflect the proportion of time spent in mechanical dyssynchrony, thereby promoting thrombus formation. Though it is recognised to be an important predictor of stroke risk, the exact relationship remains to be defined and further research is warranted. Furthermore, determining the AF burden in patients without implantable cardiac devices can be challenging.

There are also important considerations when treating patients with a high burden of AF. Although a strategy to reduce this burden may be appropriate for some patients, attempts to restore sinus rhythm is not without risk. The FibStroke study revealed that electrical and pharmacological cardioversions were related to occurrences of ischaemic stroke (46). As the majority of events occurred in patients who underwent electrical cardioversion, it could be postulated that the delivery of electrical energy may have dislodged pre-formed thrombi. However, many of the stroke events only occurred after a significant time delay (median of two days) following cardioversion. Therefore, there are likely to be other factors involved. Furthermore, there are even reports of acute thromboembolic complications following spontaneous cardioversion of AF (47,48). A potential cause for this may be linked to atrial stunning that occurs regardless of the means of cardioversion (49).

It was previously suggested that the morphology of AF as assessed on ECG may be useful for stroke risk assessment. In a study of 811 consecutive patients, Yilmaz *et al.* classified AF based on surface ECG as ‘coarse’ or ‘fine’ AF, and was able to demonstrate that patients with coarse AF had increased risk of stroke (50). The authors defined ‘coarse’ AF as the presence of undulations moving ≥1 mm from the isoelectric baseline with different morphologies and ‘fine’ AF as the presence of minimal or no undulation from the isoelectric baseline. At present, there is insufficient evidence to draw any firm conclusions. Nevertheless, if deemed reliable, classification of AF according to the different morphologies on ECG may provide a readily assessible tool to support clinical decisions.

Given the increased risk of stroke in AF, it would seem plausible that a temporal relationship might exists between these two conditions. If true, it may provide us a method of identifying patients at the point of highest stroke risk in order to instigate additional protective measures to avoid this complication. However, an initial study by ASSERT investigators revealed that only 8% of patients had subclinical AF detected within 30 days before their stroke or systemic embolism (51). Thus far, there is no strong evidence to support a temporal relationship between the episodes of AF and stroke events.

## Biological markers (‘biomarkers’)

Many biomarkers involving blood, urine and structural parameters have been studied in AF and been shown to improve the accuracy of stroke risk stratification. Despite this, their clinical applicability remains limited. Possible reasons include inter- and intra-patient and assay variability; diurnal variation of the results obtained; costs involved; strong influences of associated comorbidities and treatments in AF on these parameters; and lack of specificity. As such, these biomarkers are mainly reserved for research purposes.

### Blood-based biomarkers

In general, blood-based biomarkers may be divided into those that relate to cardiac function (troponins and natriuretic peptides), haemostatic processes (D-dimer, von Willebrand factor (vWF), soluble E-selectin and P-selectin), inflammation (interleukin-6 (IL-6) and C-reactive protein (CRP)) or ‘others’ (renal function) (**Table 3**).

#### Cardiac function

Troponins and natriuretic peptides are among the most frequently used cardiac biomarkers. Their value in a variety of cardiovascular diseases such as myocardial infarction and heart failure have previously been established (52,53). Further studies have also consistently demonstrated that levels of these biomarkers may be used to improve predictions of stroke risk in AF (54–59). A RE-LY sub-study found that elevations in troponin I and N-terminal pro-B-type natriuretic peptide (NT-proBNP) were common among AF patients (56). Both were independently related to an increased risk of stroke and there was a graded relationship such that patients with higher levels of these cardiac biomarkers were at greater risk compared to those with lower levels. The highest quartile of NT-proBNP was associated with 2.4-fold greater risk of stroke compared to the lowest quartile while the higher tertile of troponin I was associated with a 2.0-fold greater risk of stroke compared to the lowest tertile. There are several proposed mechanisms for the prognostic value of these cardiac biomarkers. In AF, unlike heart failure, B-type natriuretic peptides (BNPs) may originate from the atria (60). This is supported by the fact that restoration of sinus rhythm is associated with a rapid fall in the level of natriuretic peptides (61,62). The elevated levels of natriuretic peptides may reflect the degree of atrial stretch (63). This in turn indicates atrial dysfunction which is linked to thrombus formation (64). Meanwhile, troponins are released as a following myocardial injury which may promote a pro-thrombotic state. Furthermore, elevated levels of troponin has been associated with impaired left atrial function, as assessed by cardiac magnetic resonance imaging (MRI) (65).

#### Renal function

Another important biomarker in stroke risk stratification is renal function (17,66–68). Impaired renal function was demonstrated to be a strong predictor of stroke and systemic embolism in the ROCKET AF and ATRIA study cohorts, second only to prior stroke or TIA (17). A meta-analysis of 18 studies involving 538,479 patients with AF demonstrated that estimated glomerular filtration rate (eGFR) was an independent risk factor for stroke or systemic embolism, with worsening chronic kidney disease (CKD) being associated with a greater increased risk (69). Indeed AF patients with the most severe form of CKD requiring dialysis may have a dramatic increase of 9.8-fold in stroke risk (70). Chronic kidney disease promotes a pro-thrombotic state by its effects on the individual components of Virchow’s triad (71). It has been found to be associated with stasis of the left atrium (LA) (72,73), impaired endothelial function (74–78) and enhanced platelet activation (79,80). Furthermore, CKD is linked to the release of procoagulant and inflammatory biomarkers (80–82).

It was previously suggested that the inclusion of CKD as a risk factor may improve stroke prediction models (17). However, additional studies have found that it did not improve the discriminative capabilities of the CHADS2 and CHA2DS2-VASc scores (67,83,84). To summarise prior results, a meta-analysis of eight studies found that the inclusion of CKD resulted in a slight improvement for stroke prediction by the CHADS2 score but not with the CHA2DS2-VASc score (69). Therefore, there is currently insufficient evidence to justify the addition of CKD to the guideline-recommended CHA2DS2-VASc score. This is perhaps unsurprising given that CKD is associated with the individual component risk factors within the CHA2DS2-VASc score.

#### Haemostasis

Stroke risk in AF is strongly related to the disruption of haemostasis, leading to a pro-thrombotic state. However, the haemostatic processes are complex and involve many different pathways. Therefore, it is important to understand which of these are affected in AF. D-dimer is a small protein fragment that is released following fibrinolysis. A prospective study of 509 patients with AF, found that those with a D-dimer level of <150 ng/ml had significantly lower risk of thromboembolic events compared to those with D-dimer level of ≥150 ng/ml, 0.7% per year compared to 3.8% per year (85). Similar findings were demonstrated in other studies (86,87). In contrast, You *et al.* reported that D-dimer was not an independent risk factor for ischaemic stroke in AF despite finding a positive correlation between D-dimer levels and stroke risk scores (CHADS2 and CHA2DS2-VASc) (88). However, this study was retrospective in nature and only included non-anticoagulated patients. Overall, it does appear that D-dimer may be helpful for stroke risk stratification in AF.

Given the role of platelets in haemostasis, it would seem likely that platelet count may be associated with stroke risk. However, in a study of 124 patients with AF on non-vitamin K oral anticoagulants (NOAC), Janion-Sadowska *et al.* found no association between thrombocytopenia (platelet count <100 x 109/L) and the risk of stroke or TIA over a 55-month follow-up period (89). In contrast, Park *et al.* recently reported retrospective registry data on 10,978 patients with AF where patients with a platelet count <100 x 109/L had a significantly lower stroke risk compared to those with a normal platelet count (90). A major difference between the trials was in terms of the use of anticoagulation. About half of the patients (55.4%) in the latter trial were not anticoagulated and among those who were, warfarin was the main agent of choice (96.8%). There is limited evidence to base any firm conclusions at present although it could be that thrombocytopenia is protective against stroke in AF.

Von Willebrand factor is a glycoprotein integral to haemostasis. Raised levels of vWF has been associated with a pro-thrombotic state in AF (91–94). However, a limitation in many of these studies was that the primary outcome measure included events such as heart failure and all-cause death. Therefore, it was difficult to draw strong conclusions from them. Among those that evaluated stroke only outcomes, two studies found that high levels of vWF was linked to a greater risk of stroke (91,93). Despite demonstrating that higher levels of vWF were associated with a greater composite risk of all-cause death and stroke, Ancedy *et al.* found that the results were not significant when evaluated for stroke events only (94). Consequently, the role of vWF for stroke risk stratification in AF requires additional investigation.

#### Inflammation

There is ample evidence to support the importance of inflammation in AF. However, use of inflammatory biomarkers to predict stroke risk in this condition has been met with conflicting results. An early pilot study demonstrated that IL-6 was an independent predictor of stroke risk in AF, but not CRP (95). Subsequently, Pinto *et al.* evaluated this by comparing plasma levels of interleukin-1β, tumour necrosis factor-alpha, IL-6 and interleukin-10 (and E-selectin, P-selectin, intercellular adhesion molecule-1, vascular cell adhesion molecule-1 and vWF) in chronic AF patients with and without new-onset ischaemic stroke over a period of three years (91). Following multivariable adjustment, only IL-6 and tumour necrosis factor-alpha remained significant predictors of stroke risk. In a separate study, Aulin *et al.* postulated that levels of inflammatory markers (IL-6, CRP and fibrinogen) may be related to the risk of thromboembolism in AF (96). After adjustment for clinical risk factors, only IL-6 was found to be significant. However, use of other biomarkers (troponin, NT-proBNP and cystatin-C) attenuated the importance of IL-6 such that it was no longer predictive of stroke risk in AF. Other studies failed to demonstrate an association between thromboembolic risk in AF and levels of high-sensitivity CRP (97), IL-6 (55) or fibrinogen (98). Given the current evidence, it appears that high levels of underlying inflammation as detected by IL-6 indicates a pro-thrombotic state in AF. There is no indication that CRP or fibrinogen are useful for this purpose.

In addition to the biomarkers mentioned above, there are others that have been evaluated in AF. Many have limited supporting evidence and require further studies to confirm their possible predictive capabilities. These include mean platelet volume, matrix metalloproteinase-2, reduced nicotinamide adenine dinucleotide phosphate oxidase 2-derived peptide, soluble CD40 ligand and tissue plasminogen activator (86,97,99–102). There are also biomarkers that have not been thoroughly evaluated but thus far not been convincingly shown to be associated with stroke risk in AF. These include soluble fibrin monomer complex, antithrombin III, E-selectin, P-selectin, intercellular adhesion molecule-1, vascular cell adhesion molecule-1, prothrombin fragment F1+2, thrombin-antithrombin complexes, plasminogen activator inhibitor-1 and β-thromboglobulin (85,86,91,93,97–99,103).

### Urine biomarkers

Few urine biomarkers have been identified as possible predictors of stroke risk in AF. In the ATRIA study, presence of proteinuria was associated with a 1.5-fold increased risk of thromboembolism (68). In addition, a retrospective study demonstrated that higher levels of albuminuria were associated with greater risk of thromboembolism among patients with newly diagnosed AF (104). Possible mechanisms are: 1) albuminuria reflects early-stage CKD which has been shown to be related to stroke risk; 2) albuminuria causes an imbalance between naturally occurring pro-thrombotic and anti-thrombotic factors, such as that seen in nephrotic syndrome (105). Pignatelli *et al.* showed that higher urinary prostaglandin F2α levels were associated with a greater composite risk of stroke, TIA, myocardial infarction and coronary revascularisation during a follow-up period of 26 months (100). Furthermore, urinary 11-dehydro-thromboxane B2 has also been found to be related to a composite risk of stroke, TIA, myocardial infarction, coronary revascularisation and cardiovascular-related death among patients with AF (106). Overall, although urine biomarkers have not been comprehensively investigated in AF, they may represent an additional, simple and non-invasive method to aid stroke risk stratification.

### Structural biomarkers

Atrial fibrillation causes significant structural changes including atrial remodelling that may be detected through a variety of imaging techniques. Some of these changes have been found to predict stroke risk in AF (**Table 4**), potentially by promoting abnormal blood stasis. Early studies in this area have relied predominantly on standard transthoracic echocardiography. Recently, advanced imaging modalities with increased accuracy such as trans-oesophageal echocardiography, computed tomography and MRI have become more widely available. This has allowed the discovery of new structural biomarkers such as LA fibrosis and left atrial appendage (LAA) morphology that may be used to refine stroke risk assessment in AF. The SPAF study evaluated the role of 14 echocardiographic parameters to predict incident ischaemic stroke or systemic embolism in AF (107). The authors reported that the presence of left ventricular dysfunction and higher LA size were found to be important. Furthermore, these parameters were able to identify patients without clinical risk factors who were at higher risk of stroke. A prospective study of 2,713 patients with AF demonstrated that LA enlargement (>45mm) was linked to a 1.7-fold increased risk of ischaemic stroke or systemic embolism (108). Dakay *et al.* also found that more severe LA enlargement was associated with a greater risk of ischaemic stroke despite anticoagulation (109).Interestingly, there appears to be an association between LA size and stroke risk even in the absence of AF. In the Framingham Heart study, non-AF patients with increased LA size were found to be at greater risk of stroke and mortality during the follow-up period of eight years (110). The presence of LA enlargement may therefore be helpful to identify the subset of AF patients who remain at high-risk of stroke despite anticoagulation therapy. Furthermore, it can be assessed on transthoracic echocardiography without the need for more complex imaging techniques.

The majority of cardioembolic strokes originate from the left atrium. In the LA, the most common site of thrombus formation is within the LAA. This is a small, complex, pouch-like sac attached to the anterior portion of the LA. Due to its complex anatomical structure and narrow inlet, the LAA is prone to abnormal blood stasis predisposing to thrombus formation. These thrombi may subsequently dislodge to cause a stroke. Therefore, it is perhaps unsurprising that certain LAA features have been shown to influence stroke risk. Unfortunately, these are rarely appreciated on standard transthoracic echocardiography which remains the most commonly used imaging method. The SPAF-III study demonstrated that among AF patients, ongoing arrhythmia during trans-oesophageal assessment was associated with a lower LAA peak antegrade flow velocity (Avp) (111). Furthermore, the authors found that an LAA Avp <20cm/s was related to the presence of spontaneous echo contrast and LAA thrombus, and increased risk of cardioembolic events. Predictors of Avp <20cm/s were increasing age, higher systolic blood pressure, ischaemic heart disease and greater LA area. All of which are known risk factors for AF. In addition, the presence of spontaneous echo contrast and LAA thrombus have both been independently shown to be linked to greater stroke risk in AF (112,113).

It is now recognised that the LAA is a complex structure with significant variation between patients. A study by Di Biase *et al*. found that among AF patients planned for catheter ablation, LAA morphologies could be categorised into four main groups based on their appearances on computed tomography or MRI (114). In order of reducing frequency, these were called ‘chicken wing’ (48%), ‘cactus’ (30%), ‘windsock’ (19%) and ‘cauliflower’ (3%). After multivariable adjustment, a chicken wing morphology was associated with the lowest risk of stroke. In comparison, there was a four-fold increased stroke risk with the cactus and windsock morphologies, and eight-fold increased stroke risk with the cauliflower morphology. Similar findings were also reported elsewhere (115,116). However, a study by Khurram *et al.* failed to demonstrate any association between LAA morphology and risk of stroke or TIA (117). In addition, the authors found that there was significant inter-observer variability during determination of LAA morphology, indicating that this may be an unreliable method of assessment. Limitations of the studies assessing LAA morphology above lies in the fact that they were all retrospective in nature and included only a subset of AF patients, specifically those undergoing catheter ablation. Therefore, future prospective studies are needed to confirm whether LAA morphology may be used for stroke risk stratification in a general cohort of AF patients.

Other LAA parameters such as the number of lobes, neck dimension, overall dimension, volume, orifice diameter and trabeculations have also been studied but again further evaluation is required (117,118). Left atrial fibrosis may also represent an additional biomarker for stroke risk stratification. In a study of 178 patients with AF, LA fibrosis was assessed using late gadolinium enhancement MRI and correlated to trans-oesophageal findings (119). The authors reported that high atrial fibrosis (>20%) was linked to spontaneous echo contrast and LAA thrombus. Additionally, the presence of complex aortic plaques on trans-oesophageal echocardiography defined based on features of mobility, ulceration, pedunculation, thickness ≥4mm and location were found to be independently associated with a two-fold increased thromboembolic risk (113).

## Genetic markers

Improvements in genomic technologies have seen an increasing role for genetic testing in certain diseases. This may provide an additional element for risk stratification in AF. However, there have been few genetics studies in AF to date and they have largely focused on chromosome 4q25. It has been suggested that genetic variants on this chromosome may be related with ischaemic stroke (120,121). In a case-control study of 1,059 AF patients, after adjusting for potential confounders, FGB 455 G/A polymorphism was associated with increased cardioembolic stroke potentially through elevated fibrinogen levels (122). Factor V Leiden mutation has not been found to be predictive of thromboembolism in AF (98). Overall, more studies are needed to confirm these genetic findings. Even then, the use of genetic markers for stroke risk stratification in AF remains unrealistic at present.

# Bleeding risk assessment

A vital aspect of the management for AF includes stroke prevention. To this end, many patients require anticoagulation therapy. However, this approach is not without risk. A meta-analysis of eight RCTs found that the annual rates of major bleeding varied from 1.4 to 3.4% among patients with AF treated with warfarin (123). The risk of ICH, the most serious form of bleeding, was estimated at 0.61% per year. Similar results were reported by Fang *et al.* in a cohort of 13,559 patients with AF treated with warfarin (124). Despite the relatively low rates of ICH, 76% of these patients had severe disability or died, and ICH was associated with at least a 20-fold increased risk of 30-day mortality compared to other forms of bleeding. Given the detrimental consequences of anticoagulation-related bleeding in AF, especially with ICH, efforts should be directed at reducing this risk while maintaining adequate stroke prevention. The use of NOACs have been shown to be superior to warfarin in this regard. Two large meta-analysis have shown that NOACs, as a class of medications, have a better safety profile with less major bleeding and ICH when compared to warfarin (125,126).

It is also important to consider the timing of anticoagulation-related bleeding events. In this aspect, there appears to be an excess risk during the initial few months of treatment with vitamin K antagonist (VKA) (127). This may be due to poor anticoagulation control that eventually improves with time. However, there are likely to be additional factors involved as a similar effect was observed with dabigatran, where initial dose adjustments are rare (128). It is possible that the use of anticoagulation is simply unmasking high-risk individuals who were not identified using traditional assessment methods. Therefore, better risk profiling is necessary. Various factors based on clinical, biological and genetic markers have been shown to predict the risk of anticoagulation-related bleeding in patients with AF (**Table 5**). Some of these factors may also influence the stroke risk.

There are several bleeding risk scores designed specifically for use in an AF cohort (**Table 6**). They have previously been summarised and include a combination of different clinical, biological and genetic markers (129). In general, each risk factor is assigned a score and the sum of these scores are used to estimate annual bleeding risk in an individual who is anticoagulated. It should be noted that there are differences in the way certain risk factors (e.g. age, renal dysfunction and hypertension) have been defined between the various risk scores. Furthermore, many risk factors for bleeding contribute as well to stroke risk in AF. This highlights the complex relationship between thrombogenesis and bleeding, and represent the challenges faced by physicians when weighing up the risk and benefits of anticoagulation therapy (20).

## Clinical markers

An early study investigating the risk factors for bleeding among patients treated with warfarin found that age ≥65 years, prior stroke, history of gastrointestinal bleeding, presence of serious comorbidity (such as recent myocardial infarction or renal impairment) and AF were important predictors (130). However, the study was limited by a small sample size and heterogenous cohort. Hughes *et al.* performed a systematic review of nine studies reporting on anticoagulation-related bleeding complications in AF to demonstrate that increasing age, uncontrolled hypertension, prior myocardial infarction or ischaemic heart disease, prior stroke, anaemia, history of bleeding and concomitant use of other drugs (e.g. antiplatelets) were independent risk factors for bleeding (131). Unlike previous studies (132,133), diabetes mellitus and sex were not found to be important predictors. Conversely, age and concomitant use of antiplatelets have been consistently shown to significantly increase the risk of anticoagulation-related major bleeding (132–135). Potential explanations for the increased risk of bleeding with age may relate to changes in metabolic clearance, higher prevalence of comorbidities, degenerative vascular changes, polypharmacy and cognitive decline (136). Meanwhile, concomitant use of antiplatelets will interfere with additional haemostatic pathways that are necessary to prevent bleeding. Additional anticoagulation-related bleeding risk factors that have previously been described include excess alcohol intake and thyroid disease (133,137).

### Falls

Prior falls is perceived as a risk factor for anticoagulation-related bleeding, especially in elderly patients. Gage *et al*. demonstrated a significantly increased risk of ICH associated with the use of warfarin in AF patients deemed at high-risk of falls (138). Based on this, such patients are often deprived of anticoagulant treatment for stroke prevention with the assumption that it is harmful. However, it is important to recognise that within the same study, there was overall improvement in clinical outcomes among patients at high-risk of falls who received anticoagulation therapy, despite the increased risk of ICH. In a separate study involving 7,156 patients with AF, a history of falls was independently associated with a 3.3-fold increased risk of major bleeding (139). The authors remarked that assessment of ‘actual falls’ may be more clinically useful than the ‘falls risk’. This may provide an explanation for lack of association between falls and major bleeding events in a prospective study involving 515 patients on oral anticoagulation, where falls risk was used (140). Overall, the current evidence indicate that a history of falls may be an important risk factor for major bleeding but that this should not be the sole deterrent for anticoagulation in AF. In support of this, an earlier study by Man-Son-Hing *et al.* found that patients would need to fall an estimated 295 times per year for the risk of serious bleeding to outweigh the beneficial effects of warfarin (141).

### Malignancy

Presence of a malignant disease has been associated with increased anticoagulation-related bleeding. A study by Gitter *et al.* found that patients with a malignant condition at the time of warfarin initiation had a four-fold greater risk of major haemorrhage during a 28-month follow-up period (142). Results from a secondary analysis of a prospective RCT demonstrated that the higher risk of bleeding was also observed with other anticoagulants such as heparin and danaparoid (143). Despite the overall increased risk of anticoagulation-related bleeding with malignant conditions, there exist variations in terms of safety and efficacy between the different options for anticoagulation. In general, low-molecular weight heparin has a similar safety profile to VKA and is superior for prevention of recurrent thromboembolism (144,145). Non-vitamin K antagonist oral anticoagulants are a more convenient option to low-molecular weight heparin but may be associated with a higher risk of major bleeding with comparable effectiveness (145–147). Therefore, patients with malignant conditions who require anticoagulation therapy should be commenced on either low-molecular weight heparin or NOACs.

### Ethnicity

A previous study of 28,628 patients from the GARFIELD-AF registry demonstrated that those with an Asian background had reduced risk of major bleeding compared to other ethnicities (148). However, subsequent studies have found that while the risk of ICH is higher among non-whites in general, it was up to 4-fold higher in Asians compared to whites (149,150). Furthermore, the complication was associated with worse outcomes in this group of patients (151). Given the current evidence, additional attention should be directed towards other modifiable bleeding risk factors in Asian patients commencing anticoagulation therapy. It may also be appropriate to consider NOACs in the first-instance as these have been found to be safer alternatives to VKA in this cohort (152).

### Weight

Body weight is known to influence the distribution and clearance of anticoagulants (153). Therefore, there were concerns about the safety (and efficacy) of these medications in patients with extremes of body weight. However, studies on this topic have produced reassuring results. The risk of anticoagulation-related bleeding appears similar in underweight, and overweight or obese patients compared to those with normal body weight (154,155). In fact, some studies have suggested that obesity may even be associated with reduced rates of bleeding (156–158). Furthermore, patients with obesity and AF who were treated with a NOAC had lower risk of thromboembolism, leading to the term ‘obesity paradox’ (154–156).

## Biological markers

There are several biomarkers that may help predict anticoagulation-related bleeding. Some of these are linked to stroke risk and have already been described above (e.g. renal failure, IL-6, vWF). Perhaps one of the most important biomarkers associated with the use of VKA is the intensity of anticoagulation, measured as the international normalised ratio (INR). Higher INR levels have been found to increase the risk of anticoagulation-related bleeding, with relative risks (RR) for INR ≥4.5 of 7.9 (95% CI, 5.4 - 11.5) compared to INR <4.5 (127). It is estimated that every one unit increase in INR above 2.5 was associated with a two-fold increased risk of mortality (159). Therefore, every effort should be taken to maintain the INR of AF patients within pre-defined ranges, often between 2 - 3 (20). However, absolute INR levels alone can be misleading as a significant proportion of major bleeds occur despite the INR being in therapeutic range (160). More recently, INR variability has emerged as a more reliable assessment method for bleeding risk. A ‘labile INR’ as determined using time-in-therapeutic range (TTR) is strongly linked to future bleeding events (161–163). However, there are several limitations of TTR that are worth bearing in mind (164,165). Firstly, it assumes a linear relationship between INR measurements which may not be true. Secondly, it does not inform on short-term risks associated with extreme deviations in INR. Lastly, it fails to account for individuals with ‘missed’ monitoring periods who may represent a group at higher risk of bleeding due to reasons such as non-adherence.

Given the importance of the liver and kidneys in regulating pharmacokinetics of drugs and maintaining haemostasis, it is inevitable that fluctuations in the functions of these organs could negatively impact on anticoagulation-related bleeding. A prospective, observational study of 8,466 AF patients treated with either VKA or NOACs suggests that both abnormal renal and liver functions were associated with increased risk of major bleeding (166). The study authors defined abnormal renal function as serum creatinine >2.3 mg/dL (200 μmol/L), prior renal transplantation or receiving chronic dialysis, and abnormal liver function as cirrhosis, elevated liver transaminases or alkaline phosphatase >3 times above the upper limit of normal, or bilirubin >2 times above the upper limit of normal. Similar findings were reported in a separate large cohort study of 7,141 AF patients receiving rivaroxaban (167). Furthermore, Banerjee *et al.* reported that lower levels of eGFR were related to a greater risk of major bleeding over a study period of 2.5 years (66).

Anaemia has also been linked to increased bleeding risk (130,131,168). The underlying mechanism remains unclear but there is some evidence to suggest that platelet aggregation is impaired by a reduced red blood cell count (169). Furthermore, the anaemia may indicate concealed bleeding that becomes manifest with anticoagulation therapy.

The use of IL-6 as a predictor of anticoagulation-related bleeding remains controversial. A large cohort study in AF patients found that IL-6 was independently associated with bleeding following adjustment for clinical risk factors and other biomarkers (troponin, NT-proBNP and cystatin-C) (96). Meanwhile, although a separate large cohort study initially demonstrated the relationship between IL-6 and bleeding, the results were not statistically significant once other biomarkers were taken into account (170). Neither of these studies found CRP to be important in the relationship with bleeding.

Similar to the stroke findings as discussed above, the study by Janion-Sadowska *et al.* found no association between thrombocytopenia (platelet count <100 x 109/L) and risk of bleeding (89). In contrast, Park *et al.* reported that patients with a platelet count <100 x 109/L had a significantly increased risk of bleeding events compared to those with a normal platelet count (HR 2.19 (95% CI, 1.77 - 2.70)) (90). Despite limited evidence on the matter, it seems likely that a low platelet count could increase the risk of bleeding in AF.

In addition to the biomarkers above, there are several others that have been associated with anticoagulation-related bleeding including vWF, high-sensitivity troponin and growth differentiation factor-15 (marker of oxidative stress). Roldan *et al.* showed that patients with high levels of vWF had a 4.5-fold increased risk of major bleeding (92). Using the ARISTOTLE cohort, Hijazi *et al.* demonstrated that both high-sensitivity troponin and growth differentiation factor-15 were the strongest predictors of major bleeding when compared to traditional risk factors such as age, haemoglobin, previous bleeding, congestive heart failure, previous stroke or TIA, hypertension and diabetes mellitus (134). Studies on NT-proBNP have not found it to be useful for predicting anticoagulation-related bleeding (56–58). Overall, there is limited research to support the ‘real world’ role of these biomarkers in relation to bleeding risk assessment, given that bleeding risk is dynamic and changes with addressing modifiable risks, and that many biomarkers are non-specific and likely to reflect a sick patient or ‘sick heart’.

## Genetic markers

Polymorphism of cytochrome P450 2C9 has been linked to an increased risk of major bleeding through its effects on the metabolism and action of warfarin (171). It may also have important implications on warfarin dose requirements (172). However, as mentioned above, there is currently limited evidence on the role for genetic markers in AF.

# Limitations of risk scores

Risk scores are useful as they provide a rapid tool to guide treatment decisions in AF and highlight bleeding risk factors that deserve attention. However, it is important to recognise that the risk scores in AF have been simplified to provide physicians with a reliable yet useable tool for daily clinical practice. As a result, most are subject to several limitations and are at best, only modestly robust at predicting individual stroke risk (173).

First, not all risk factors may be included in certain risk scores. Second, they use a ‘one size fits all’ approach and do not account for the heterogenous nature within the AF population. Third, they fail to adequately consider the differential weight of individual risk factors. Fourth, they fail to consider the degree or severity of individual risk factors. Fifth, many risk scores were developed using older definition of diseases that may have subsequently evolved over time. Finally, studies have often correlated stroke occurrences during long periods of follow-up to risk factors measured at baseline, and risk changes with increasing age and incident risk factors. Indeed, recent attention has been directed towards the dynamic nature of risk profiles in AF patients (174–176). Chao *et al.* found the majority of patients with AF (89.4%) developed ≥1 new risk factor(s) prior to presenting with an ischaemic stroke (176). Indeed, a change in CHA2DS2-VASc score was demonstrated to be strongly predictive of ischaemic stroke. The study highlights the importance of regular stroke risk assessments in AF. Therefore, stroke and bleeding risk stratification should be undertaken by clinicians as a continuous process with specific focus on preventing the development of additional risk factors. Furthermore, in addition to the dynamic nature of risk, therapeutic options for AF are expanding. As more effective and safer therapies are introduced, we may need to re-evaluate the threshold for initiating anticoagulation.

# Conclusion

In conclusion, there are a variety of clinical, electrical, biological and genetic markers to guide stroke and bleeding risk assessments in AF. Furthermore, risk schemas provide a structured, standardised and rapid tool for this purpose.

# Disclosures

WYD and SLH: None declared.

DG: Speaker for Bayer, BMS/Pfizer, Boehringer Ingelheim, Daiichi-Sankyo, Medtronic, Biosense Webster and Boston Scientific. Proctor for Abbott. Research Grants from Medtronic, Biosense Webster and Boston Scientific.

GYHL: Consultant for Bayer/Janssen, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Novartis, Verseon and Daiichi-Sankyo. Speaker for Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, and Daiichi-Sankyo. No fees are directly received personally.

DL has received investigator-initiated educational grants from Bristol-Myers Squibb and Boehringer Ingelheim; has been a speaker for Boehringer Ingelheim, Bayer, and Bristol-Myers Squibb/Pfizer; and has consulted for Bristol-Myers Squibb, Bayer, Boehringer Ingelheim, and Daiichi-Sankyo.

The funders had NO role in the submitted paper. All authors declare no conflict of interest.

# References

1. Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: A global burden of disease 2010 study. Circulation. 2014 Feb;129(8):837–47.

2. Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation. 1998 Sep;98(10):946–52.

3. Stewart S, Hart CL, Hole DJ, McMurray JJV V. A population-based study of the long-term risks associated with atrial fibrillation: 20-Year follow-up of the Renfrew/Paisley study. Am J Med. 2002 Oct;113(5):359–64.

4. Thrall G, Lane D, Carroll D, Lip GYH. Quality of life in patients with atrial fibrillation: a systematic review. Am J Med. 2006 May;119(5):448.e1-19.

5. Vermond RA, Geelhoed B, Verweij N, Tieleman RG, Van der Harst P, Hillege HL, et al. Incidence of Atrial Fibrillation and Relationship With Cardiovascular Events, Heart Failure, and Mortality A Community-Based Study From the Netherlands. J Am Coll Cardiol. 2015 Sep;66(9):1000–7.

6. Stewart S, Murphy NF, Walker A, McGuire A, McMurray JJ V. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart. 2004 Mar;90(3):286–92.

7. Kim MH, Johnston SS, Chu B-C, Dalal MR, Schulman KL. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circ Cardiovasc Qual Outcomes. 2011 May;4(3):313–20.

8. Lip GYH, Kakar P, Watson T. Atrial fibrillation - the growing epidemic. Vol. 93, Heart (British Cardiac Society). England, England; 2007. p. 542–3.

9. Morillo CA, Banerjee A, Perel P, Wood D, Jouven X. Atrial fibrillation: the current epidemic. J Geriatr Cardiol. 2017 Mar;14(3):195–203.

10. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006 Jul;114(2):119–25.

11. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby J V, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001 May;285(18):2370–5.

12. Krijthe BP, Kunst A, Benjamin EJ, Lip GYH, Franco OH, Hofman A, et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J. 2013 Sep;34(35):2746–51.

13. Wolf PA, Dawber TR, Thomas HEJ, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology. 1978 Oct;28(10):973–7.

14. Britton M, Gustafsson C. Non-rheumatic atrial fibrillation as a risk factor for stroke. Stroke. 1985;16(2):182–8.

15. Lin HJ, Wolf PA, Kelly-Hayes M, Beiser AS, Kase CS, Benjamin EJ, et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke. 1996 Oct;27(10):1760–4.

16. Fox KAA, Lucas JE, Pieper KS, Bassand J-P, Camm AJ, Fitzmaurice DA, et al. Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation. BMJ Open. 2017 Dec;7(12):e017157.

17. Piccini JP, Stevens SR, Chang Y, Singer DE, Lokhnygina Y, Go AS, et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: Validation of the R2CHADS2 index in the ROCKET AF. Circulation. 2013 Jan 15;127(2):224–32.

18. Lip GYHH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGMGM, Andresen D, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010 Feb;137(2):263–72.

19. Hart RG, Stroke Risk in Atrial Fibrillation Working Group. Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation. Stroke. 2008 Jun;39(6):1901–10.

20. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016 Oct;37(38):2893–962.

21. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JCJ, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014 Dec;64(21):e1-76.

22. National Institute for Health and Care Excellence. Guideline on atrial fibrillation: management [Internet]. 2014 [cited 2019 Sep 3]. p. 1–45. Available from: https://www.nice.org.uk/guidance/cg180/resources/atrial-fibrillation-management-pdf-35109805981381

23. Lip GYH, Banerjee A, Boriani G, Chiang CE, Fargo R, Freedman B, et al. Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report. Chest. 2018 Nov;154(5):1121–201.

24. Chiang C-E, Okumura K, Zhang S, Chao T-F, Siu C-W, Wei Lim T, et al. 2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation. J arrhythmia. 2017 Aug;33(4):345–67.

25. Friberg L, Rosenqvist M, Lip GYH. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012 Jun;33(12):1500–10.

26. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994 Jul;154(13):1449–57.

27. Lip GYH, Skjoth F, Rasmussen LH, Larsen TB. Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score. J Am Coll Cardiol. 2015 Apr;65(14):1385–94.

28. Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: A systematic review. Neurology. 2007 Aug;69(6):546–54.

29. Olesen JB, Fauchier L, Lane DA, Taillandier S, Lip GYH. Risk factors for stroke and thromboembolism in relation to age among patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. Chest. 2012 Jan;141(1):147–53.

30. Fang MC, Singer DE, Chang Y, Hylek EM, Henault LE, Jensvold NG, et al. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. Circulation. 2005 Sep;112(12):1687–91.

31. Poli D, Antonucci E, Grifoni E, Abbate R, Gensini GF, Prisco D. Gender differences in stroke risk of atrial fibrillation patients on oral anticoagulant treatment. Thromb Haemost. 2009 May;101(5):938–42.

32. Renoux C, Coulombe J, Suissa S. Revisiting sex differences in outcomes in non-valvular atrial fibrillation: a population-based cohort study. Eur Heart J. 2017 May;38(19):1473–9.

33. Nielsen PB, Skjoth F, Overvad TF, Larsen TB, Lip GYH. Female Sex Is a Risk Modifier Rather Than a Risk Factor for Stroke in Atrial Fibrillation: Should We Use a CHA2DS2-VA Score Rather Than CHA2DS2-VASc? Circulation. 2018 Feb;137(8):832–40.

34. Friberg L, Hammar N, Rosenqvist M. Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation. Eur Heart J. 2010 Apr;31(8):967–75.

35. Hart RG, Pearce LA, Rothbart RM, McAnulty JH, Asinger RW, Halperin JL. Stroke with intermittent atrial fibrillation: Incidence and predictors during aspirin therapy. J Am Coll Cardiol. 2000 Jan;35(1):183–7.

36. Hohnloser SH, Pajitnev D, Pogue J, Healey JS, Pfeffer MA, Yusuf S, et al. Incidence of Stroke in Paroxysmal Versus Sustained Atrial Fibrillation in Patients Taking Oral Anticoagulation or Combined Antiplatelet Therapy. An ACTIVE W Substudy. J Am Coll Cardiol. 2007 Nov;50(22):2156–61.

37. Hughes M, Lip GYH. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost. 2008 Feb;99(2):295–304.

38. Ganesan AN, Chew DP, Hartshorne T, Selvanayagam JB, Aylward PE, Sanders P, et al. The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: a systematic review and meta-analysis. Eur Heart J. 2016 May;37(20):1591–602.

39. Link MS, Giugliano RP, Ruff CT, Scirica BM, Huikuri H, Oto A, et al. Stroke and Mortality Risk in Patients with Various Patterns of Atrial Fibrillation: Results from the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48). Circ Arrhythmia Electrophysiol. 2017 Jan;10(1):1–7.

40. Glotzer T V., Hellkamp AS, Zimmerman J, Sweeney MO, Yee R, Marinchak R, et al. Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: Report of the atrial diagnostics ancillary study of the MOde Selection Trial (MOST). Circulation. 2003 Apr;107(12):1614–9.

41. Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med. 2012 Jan;366(2):120–9.

42. Capucci A, Santini M, Padeletti L, Gulizia M, Botto G, Boriani G, et al. Monitored atrial fibrillation duration predicts arterial embolic events in patients suffering from bradycardia and atrial fibrillation implanted with antitachycardia pacemakers. J Am Coll Cardiol. 2005 Nov;46(10):1913–20.

43. Boriani G, Glotzer T V, Santini M, West TM, De Melis M, Sepsi M, et al. Device-detected atrial fibrillation and risk for stroke: an analysis of >10,000 patients from the SOS AF project (Stroke preventiOn Strategies based on Atrial Fibrillation information from implanted devices). Eur Heart J. 2014 Feb;35(8):508–16.

44. Go AS, Reynolds K, Yang J, Gupta N, Lenane J, Sung SH, et al. Association of Burden of Atrial Fibrillation With Risk of Ischemic Stroke in Adults With Paroxysmal Atrial Fibrillation: The KP-RHYTHM Study. JAMA Cardiol. 2018 Jul;3(7):601–8.

45. Chu S-Y, Jiang J, Wang Y-L, Sheng Q-H, Zhou J, Ding Y-S. Pacemaker-detected atrial fibrillation burden and risk of ischemic stroke or thromboembolic events—A cohort study. Hear Lung. 2019 Jul;000.

46. Palomaki A, Mustonen P, Hartikainen JEK, Nuotio I, Kiviniemi T, Ylitalo A, et al. Strokes after cardioversion of atrial fibrillation--The FibStroke study. Int J Cardiol. 2016 Jan;203:269–73.

47. Weigner MJ, Caulfield TA, Danias PG, Silverman DI, Manning WJ. Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours. Ann Intern Med. 1997 Apr;126(8):615–20.

48. Michael JA, Stiell IG, Agarwal S, Mandavia DP. Cardioversion of paroxysmal atrial fibrillation in the emergency department. Ann Emerg Med. 1999 Apr;33(4):379–87.

49. Khan IA. Atrial stunning: basics and clinical considerations. Int J Cardiol. 2003 Dec;92(2–3):113–28.

50. Yilmaz MB, Guray Y, Guray U, Cay S, Caldir V, Biyikoglu SF, et al. Fine vs. coarse atrial fibrillation: which one is more risky? Cardiology. 2007;107(3):193–6.

51. Brambatti M, Connolly SJ, Gold MR, Morillo CA, Capucci A, Muto C, et al. Temporal relationship between subclinical atrial fibrillation and embolic events. Circulation. 2014 May;129(21):2094–9.

52. Roffi M, Patrono C, Collet J-P, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of . Eur Heart J. 2016 Jan;37(3):267–315.

53. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of. Eur Heart J. 2016 Jul;37(27):2129–200.

54. Sadanaga T, Kohsaka S, Mitamura H, Ogawa S. Elevated B-type natriuretic peptide level as a marker of subsequent thromboembolic events in patients with atrial fibrillation. Heart Vessels. 2011 Sep;26(5):530–5.

55. Roldan V, Marin F, Diaz J, Gallego P, Jover E, Romera M, et al. High sensitivity cardiac troponin T and interleukin-6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation. J Thromb Haemost. 2012 Aug;10(8):1500–7.

56. Hijazi Z, Oldgren J, Andersson U, Connolly SJ, Ezekowitz MD, Hohnloser SH, et al. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy. Circulation. 2012 Apr;125(13):1605–16.

57. Hijazi Z, Wallentin L, Siegbahn A, Andersson U, Christersson C, Ezekowitz J, et al. N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). J Am Coll Cardiol. 2013 Jun;61(22):2274–84.

58. Roldan V, Vilchez JA, Manzano-Fernandez S, Jover E, Galvez J, Puche CM, et al. Usefulness of N-terminal pro-B-type natriuretic Peptide levels for stroke risk prediction in anticoagulated patients with atrial fibrillation. Stroke. 2014 Mar;45(3):696–701.

59. Hayashi K, Tsuda T, Nomura A, Fujino N, Nohara A, Sakata K, et al. Impact of B-Type Natriuretic Peptide Level on Risk Stratification of Thromboembolism and Death in Patients With Nonvalvular Atrial Fibrillation- The Hokuriku-Plus AF Registry. Circ J. 2018 Apr;82(5):1271–8.

60. Goetze JP, Friis-Hansen L, Rehfeld JF, Nilsson B, Svendsen JH. Atrial secretion of B-type natriuretic peptide. Eur Heart J. 2006 Jul;27(14):1648–50.

61. Yamada T, Murakami Y, Okada T, Okamoto M, Shimizu T, Toyama J, et al. Plasma Atrial Natriuretic Peptide and Brain Natriuretic Peptide Levels After Radiofrequency Catheter Ablation of Atrial Fibrillation. Am J Cardiol. 2006 Jun 15;97(12):1741–4.

62. Wozakowska-Kapłon B. Effect of sinus rhythm restoration on plasma brain natriuretic peptide in patients with atrial fibrillation. Am J Cardiol. 2004 Jun 15;93(12):1555–8.

63. Mantymaa P, Vuolteenaho O, Marttila M, Ruskoaho H. Atrial stretch induces rapid increase in brain natriuretic peptide but not in atrial natriuretic peptide gene expression in vitro. Endocrinology. 1993 Sep;133(3):1470–3.

64. Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography. Ann Intern Med. 1998 Apr;128(8):639–47.

65. Natale M, Behnes M, Kim S-H, Hoffmann J, Reckord N, Hoffmann U, et al. High sensitivity troponin T and I reflect left atrial function being assessed by cardiac magnetic resonance imaging. Ann Clin Biochem. 2018 Mar;55(2):264–75.

66. Banerjee A, Fauchier L, Vourc’H P, Andres CR, Taillandier S, Halimi JM, et al. A prospective study of estimated glomerular filtration rate and outcomes in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. Chest. 2014 Jun;145(6):1370–82.

67. Apostolakis S, Guo Y, Lane DA, Buller H, Lip GYH. Renal function and outcomes in anticoagulated patients with non-valvular atrial fibrillation: the AMADEUS trial. Eur Heart J. 2013 Dec;34(46):3572–9.

68. Go AS, Fang MC, Udaltsova N, Chang Y, Pomernacki NK, Borowsky L, et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation. 2009 Mar 17;119(10):1363–9.

69. Zeng W-TT, Sun X-TT, Tang K, Mei W-YY, Liu L-JJ, Xu Q, et al. Risk of thromboembolic events in atrial fibrillation with chronic kidney disease. Stroke. 2015 Jan 3;46(1):157–63.

70. Vazquez E, Sanchez-Perales C, Garcia-Garcia F, Castellano P, Garcia-Cortes M-J, Liebana A, et al. Atrial fibrillation in incident dialysis patients. Kidney Int. 2009 Aug;76(3):324–30.

71. Lau YC, Proietti M, Guiducci E, Blann AD, Lip GYH. Atrial Fibrillation and Thromboembolism in Patients With Chronic Kidney Disease. J Am Coll Cardiol. 2016 Sep;68(13):1452–64.

72. Kizawa S, Ito T, Akamatsu K, Ichihara N, Nogi S, Miyamura M, et al. Chronic Kidney Disease as a Possible Predictor of Left Atrial Thrombogenic Milieu Among Patients with Nonvalvular Atrial Fibrillation. Am J Cardiol. 2018 Dec;122(12):2062–7.

73. Providencia R, Fernandes A, Paiva L, Faustino A, Barra S, Botelho A, et al. Decreased glomerular filtration rate and markers of left atrial stasis in patients with nonvalvular atrial fibrillation. Cardiology. 2013;124(1):3–10.

74. Kopel T, Kaufman JS, Hamburg N, Sampalis JS, Vita JA, Dember LM. Endothelium-Dependent and -Independent Vascular Function in Advanced Chronic Kidney Disease. Clin J Am Soc Nephrol. 2017 Oct;12(10):1588–94.

75. Bolton CH, Downs LG, Victory JGG, Dwight JF, Tomson CRV, Mackness MI, et al. Endothelial dysfunction in chronic renal failure: roles of lipoprotein oxidation and pro-inflammatory cytokines. Nephrol Dial Transplant. 2001 Jun;16(6):1189–97.

76. Bartnicki P, Kowalczyk M, Franczyk-Skora B, Baj Z, Rysz J. Evaluation of Endothelial (dys)Function, Left Ventricular Structure and Function in Patients with Chronic Kidney Disease. Curr Vasc Pharmacol. 2016;14(4):360–7.

77. Carrero JJ, Kyriazis J, Sonmez A, Tzanakis I, Qureshi AR, Stenvinkel P, et al. Prolactin levels, endothelial dysfunction, and the risk of cardiovascular events and mortality in patients with CKD. Clin J Am Soc Nephrol. 2012 Feb;7(2):207–15.

78. Heintz B, Schmidt P, Maurin N, Kirsten R, Nelson K, Wieland D, et al. Endothelin-1 potentiates ADP-induced platelet aggregation in chronic renal failure. Ren Fail. 1994;16(4):481–9.

79. Thijs A, Nanayakkara PWB, Ter Wee PM, Huijgens PC, van Guldener C, Stehouwer CDA. Mild-to-moderate renal impairment is associated with platelet activation: a cross-sectional study. Clin Nephrol. 2008 Oct;70(4):325–31.

80. Landray MJ, Wheeler DC, Lip GYH, Newman DJ, Blann AD, McGlynn FJ, et al. Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study. Am J Kidney Dis. 2004 Feb;43(2):244–53.

81. Shlipak MG, Fried LF, Crump C, Bleyer AJ, Manolio TA, Tracy RP, et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation. 2003 Jan;107(1):87–92.

82. Keller C, Katz R, Cushman M, Fried LF, Shlipak M. Association of kidney function with inflammatory and procoagulant markers in a diverse cohort: a cross-sectional analysis from the Multi-Ethnic Study of Atherosclerosis (MESA). BMC Nephrol. 2008 Aug;9:9.

83. Roldan V, Marin F, Manzano-Fernandez S, Fernandez H, Gallego P, Valdes M, et al. Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation? Thromb Haemost. 2013 May;109(5):956–60.

84. Banerjee A, Fauchier L, Vourc’h P, Andres CR, Taillandier S, Halimi JM, et al. Renal impairment and ischemic stroke risk assessment in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. J Am Coll Cardiol. 2013 May;61(20):2079–87.

85. Nozawa T, Inoue H, Hirai T, Iwasa A, Okumura K, Lee J-D, et al. D-dimer level influences thromboembolic events in patients with atrial fibrillation. Int J Cardiol. 2006 Apr;109(1):59–65.

86. Vene N, Mavri A, Kosmelj K, Stegnar M. High D-dimer levels predict cardiovascular events in patients with chronic atrial fibrillation during oral anticoagulant therapy. Thromb Haemost. 2003 Dec;90(6):1163–72.

87. Sadanaga T, Sadanaga M, Ogawa S. Evidence That D-Dimer Levels Predict Subsequent Thromboembolic and Cardiovascular Events in Patients With Atrial Fibrillation During Oral Anticoagulant Therapy. J Am Coll Cardiol. 2010;55(20):2225–31.

88. You L-R, Tang M. The association of high D-dimer level with high risk of ischemic stroke in nonvalvular atrial fibrillation patients: A retrospective study. Medicine (Baltimore). 2018 Oct;97(43):e12622.

89. Janion-Sadowska A, Papuga-Szela E, Lukaszuk R, Chrapek M, Undas A. Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Thrombocytopenia. J Cardiovasc Pharmacol. 2018 Sep;72(3):153–60.

90. Park J, Cha M-J, Choi Y-J, Lee E, Moon I, Kwak S, et al. Prognostic efficacy of platelet count in patients with nonvalvular atrial fibrillation. Heart Rhythm. 2019 Feb;16(2):197–203.

91. Pinto A, Tuttolomondo A, Casuccio A, Di Raimondo D, Di Sciacca R, Arnao V, et al. Immuno-inflammatory predictors of stroke at follow-up in patients with chronic non-valvular atrial fibrillation (NVAF). Clin Sci (Lond). 2009 May;116(10):781–9.

92. Roldan V, Marin F, Muina B, Torregrosa JM, Hernandez-Romero D, Valdes M, et al. Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients. J Am Coll Cardiol. 2011 Jun;57(25):2496–504.

93. Krishnamoorthy S, Khoo CW, Lim HS, Lane DA, Pignatelli P, Basili S, et al. Prognostic role of plasma von Willebrand factor and soluble E-selectin levels for future cardiovascular events in a “real-world” community cohort of patients with atrial fibrillation. Eur J Clin Invest. 2013 Oct;43(10):1032–8.

94. Ancedy Y, Berthelot E, Lang S, Ederhy S, Boyer-Chatenet L, Di Angelantonio E, et al. Is von Willebrand factor associated with stroke and death at mid-term in patients with non-valvular atrial fibrillation? Arch Cardiovasc Dis. 2018 May;111(5):357–69.

95. Conway DS g, Buggins P, Hughes E, Lip GYH. Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation. Am Heart J. 2004 Sep;148(3):462–6.

96. Aulin J, Siegbahn A, Hijazi Z, Ezekowitz MD, Andersson U, Connolly SJ, et al. Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation. Am Heart J. 2015 Dec;170(6):1151–60.

97. Ehrlich JR, Kaluzny M, Baumann S, Lehmann R, Hohnloser SH. Biomarkers of structural remodelling and endothelial dysfunction for prediction of cardiovascular events or death in patients with atrial fibrillation. Clin Res Cardiol. 2011 Nov;100(11):1029–36.

98. Feinberg WM, Pearce LA, Hart RG, Cushman M, Cornell ES, Lip GYH, et al. Markers of thrombin and platelet activity in patients with atrial fibrillation: correlation with stroke among 1531 participants in the stroke prevention in atrial fibrillation III study. Stroke. 1999 Dec;30(12):2547–53.

99. Choi S-W, Kim B-B, Choi D-H, Park G, Shin BC, Song H, et al. Stroke or left atrial thrombus prediction using antithrombin III and mean platelet volume in patients with nonvalvular atrial fibrillation. Clin Cardiol. 2017 Nov;40(11):1013–9.

100. Pignatelli P, Pastori D, Carnevale R, Farcomeni A, Cangemi R, Nocella C, et al. Serum NOX2 and urinary isoprostanes predict vascular events in patients with atrial fibrillation. Thromb Haemost. 2015 Mar;113(3):617–24.

101. Ha S-I, Choi D-H, Ki Y-J, Yang J-S, Park G, Chung J-W, et al. Stroke prediction using mean platelet volume in patients with atrial fibrillation. Platelets. 2011;22(6):408–14.

102. Ferro D, Loffredo L, Polimeni L, Fimognari F, Villari P, Pignatelli P, et al. Soluble CD40 ligand predicts ischemic stroke and myocardial infarction in patients with nonvalvular atrial fibrillation. Arterioscler Thromb Vasc Biol. 2007 Dec;27(12):2763–8.

103. Rivera-Caravaca JM, Roldan V, Romera M, Esteve-Pastor MA, Valdes M, Lip GYH, et al. Soluble Fibrin Monomer Complex and Prediction of Cardiovascular Events in Atrial Fibrillation: The Observational Murcia Atrial Fibrillation Project. J Gen Intern Med. 2018 Jun;33(6):847–54.

104. He H, Guo J, Zhang A. The value of urine albumin in predicting thromboembolic events for patients with non-valvular atrial fibrillation. Int J Cardiol. 2016 Oct;221:827–30.

105. Gigante A, Barbano B, Sardo L, Martina P, Gasperini ML, Labbadia R, et al. Hypercoagulability and nephrotic syndrome. Curr Vasc Pharmacol. 2014 May;12(3):512–7.

106. Pastori D, Pignatelli P, Farcomeni A, Cangemi R, Hiatt WR, Bartimoccia S, et al. Urinary 11-dehydro-thromboxane B2 is associated with cardiovascular events and mortality in patients with atrial fibrillation. Am Heart J. 2015 Sep;170(3):490-7.e1.

107. Predictors of thromboembolism in atrial fibrillation: II. Echocardiographic features of patients at risk. The Stroke Prevention in Atrial Fibrillation Investigators. Ann Intern Med. 1992 Jan;116(1):6–12.

108. Hamatani Y, Ogawa H, Takabayashi K, Yamashita Y, Takagi D, Esato M, et al. Left atrial enlargement is an independent predictor of stroke and systemic embolism in patients with non-valvular atrial fibrillation. Sci Rep. 2016 Aug 3;6:31042.

109. Dakay K, Chang AD, Hemendinger M, Cutting S, McTaggart RA, Jayaraman M V., et al. Left Atrial Enlargement and Anticoagulation Status in Patients with Acute Ischemic Stroke and Atrial Fibrillation. J Stroke Cerebrovasc Dis. 2018 Jan;27(1):192–7.

110. Benjamin EJ, D’Agostino RB, Belanger AJ, Wolf PA, Levy D. Left atrial size and the risk of stroke and death. The Framingham Heart Study. Circulation. 1995 Aug;92(4):835–41.

111. Goldman ME, Pearce LA, Hart RG, Zabalgoitia M, Asinger RW, Safford R, et al. Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: I. Reduced flow velocity in the left atrial appendage (The stroke prevention in atrial fibrillation [SPAF-III] study). J Am Soc Echocardiogr. 1999 Dec;12(12):1080–7.

112. Leung DYC, Black IW, Cranney GB, Hopkins AP, Walsh WF. Prognostic implications of left atrial spontaneous echo contrast in nonvalvular atrial fibrillation. J Am Coll Cardiol. 1994 Sep;24(3):755–62.

113. Zabalgoitia M, Halperin JL, Pearce LA, Blackshear JL, Asinger RW, Hart RG. Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke Prevention in Atrial Fibrillation III Investigators. J Am Coll Cardiol. 1998 Jun;31(7):1622–6.

114. Di Biase L, Santangeli P, Anselmino M, Mohanty P, Salvetti I, Gili S, et al. Does the left atrial appendage morphology correlate with the risk of stroke in patients with atrial fibrillation? Results from a multicenter study. J Am Coll Cardiol. 2012 Aug 7;60(6):531–8.

115. Kong B, Liu Y, Hu H, Wang L, Fan Y, Mei Y, et al. Left atrial appendage morphology in patients with atrial fibrillation in China: implications for stroke risk assessment from a single center study. Chin Med J (Engl). 2014;127(24):4210–4.

116. Kimura T, Takatsuki S, Inagawa K, Katsumata Y, Nishiyama T, Nishiyama N, et al. Anatomical characteristics of the left atrial appendage in cardiogenic stroke with low CHADS2 scores. Heart Rhythm. 2013;10(6):921–5.

117. Khurram IM, Dewire J, Mager M, Maqbool F, Zimmerman SL, Zipunnikov V, et al. Relationship between left atrial appendage morphology and stroke in patients with atrial fibrillation. Heart Rhythm. 2013 Dec;10(12):1843–9.

118. Beinart R, Heist EK, Newell JB, Holmvang G, Ruskin JN, Mansour M. Left atrial appendage dimensions predict the risk of Stroke/TIA in patients with atrial fibrillation. J Cardiovasc Electrophysiol. 2011 Jan;22(1):10–5.

119. Akoum N, Fernandez G, Wilson B, Mcgann C, Kholmovski E, Marrouche N. Association of atrial fibrosis quantified using LGE-MRI with atrial appendage thrombus and spontaneous contrast on transesophageal echocardiography in patients with atrial fibrillation. J Cardiovasc Electrophysiol. 2013 Oct;24(10):1104–9.

120. Gretarsdottir S, Thorleifsson G, Manolescu A, Styrkarsdottir U, Helgadottir A, Gschwendtner A, et al. Risk variants for atrial fibrillation on chromosome 4q25 associate with ischemic stroke. Ann Neurol. 2008 Oct;64(4):402–9.

121. Lemmens R, Buysschaert I, Geelen V, Fernandez-Cadenas I, Montaner J, Schmidt H, et al. The association of the 4q25 susceptibility variant for atrial fibrillation with stroke is limited to stroke of cardioembolic etiology. Stroke. 2010 Sep;41(9):1850–7.

122. Hu X, Wang J, Li Y, Wu J, Qiao S, Xu S, et al. The β-fibrinogen gene 455G/A polymorphism associated with cardioembolic stroke in atrial fibrillation with low CHA2DS2-VaSc score. Sci Rep. 2017;7(1):1–7.

123. Agarwal S, Hachamovitch R, Menon V. Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: A meta-analysis. Arch Intern Med. 2012 Apr;172(8):623–31.

124. Fang MC, Go AS, Chang Y, Hylek EM, Henault LE, Jensvold NG, et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med. 2007 Aug;120(8):700–5.

125. Gomez-Outes A, Terleira-Fernandez AI, Calvo-Rojas G, Suarez-Gea ML, Vargas-Castrillon E. Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups. Thrombosis. 2013;2013:640723.

126. Xue Z, Zhang H. Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Asians With Atrial Fibrillation: Meta-Analysis of Randomized Trials and Real-World Studies. Stroke. 2019 Oct;50(10):2819–28.

127. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D’Angelo A, et al. Bleeding complications of oral anticoagulant treatment: An inception-cohort, prospective collaborative study (ISCOAT). Lancet. 1996 Aug;348(9025):423–8.

128. Beyer-Westendorf J, Ebertz F, Forster K, Gelbricht V, Michalski F, Kohler C, et al. Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. Thromb Haemost. 2015 Jun;113(6):1247–57.

129. Zulkifly H, Lip GYH, Lane DA. Bleeding Risk Scores in Atrial Fibrillation and Venous Thromboembolism. Am J Cardiol. 2017 Oct;120(7):1139–45.

130. Landefeld CS, Goldman L, Goldman OL, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med. 1989 Aug;87(2):144–52.

131. Hughes M, Lip GYH. Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: a systematic review. QJM. 2007 Oct;100(10):599–607.

132. Kuijer PM, Hutten BA, Prins MH, Buller HR. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med. 1999 Mar;159(5):457–60.

133. Shireman TI, Mahnken JD, Howard PA, Kresowik TF, Hou Q, Ellerbeck EF. Development of a contemporary bleeding risk model for elderly warfarin recipients. Chest. 2006 Nov;130(5):1390–6.

134. Hijazi Z, Oldgren J, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, et al. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet (London, England). 2016 Jun;387(10035):2302–11.

135. Schalekamp T, Klungel OH, Souverein PC, de Boer A. Effect of oral antiplatelet agents on major bleeding in users of coumarins. Thromb Haemost. 2008 Dec;100(6):1076–83.

136. Palareti G, Cosmi B. Bleeding with anticoagulation therapy - who is at risk, and how best to identify such patients. Thromb Haemost. 2009 Aug;102(2):268–78.

137. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGMGM, Lip GYH. H, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010 Nov;138(5):1093–100.

138. Gage BF, Birman-Deych E, Kerzner R, Radford MJ, Nilasena DS, Rich MW. Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. Am J Med. 2005 Jun;118(6):612–7.

139. Banerjee A, Clementy N, Haguenoer K, Fauchier L, Lip GYH. Prior history of falls and risk of outcomes in atrial fibrillation: the Loire Valley Atrial Fibrillation Project. Am J Med. 2014 Oct;127(10):972–8.

140. Donze J, Clair C, Hug B, Rodondi N, Waeber G, Cornuz J, et al. Risk of falls and major bleeds in patients on oral anticoagulation therapy. Am J Med. 2012 Aug;125(8):773–8.

141. Man-Son-Hing M, Nichol G, Lau A, Laupacis A. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med. 1999 Apr;159(7):677–85.

142. Gitter MJ, Jaeger TM, Petterson TM, Gersh BJ, Silverstein MD. Bleeding and thromboembolism during anticoagulant therapy: a population-based study in Rochester, Minnesota. Mayo Clin Proc. 1995 Aug;70(8):725–33.

143. Wester JP, de Valk HW, Nieuwenhuis HK, Brouwer CB, van der Graaf Y, Meuwissen OJ, et al. Risk factors for bleeding during treatment of acute venous thromboembolism. Thromb Haemost. 1996 Nov;76(5):682–8.

144. Lee AYY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003 Jul;349(2):146–53.

145. Posch F, Konigsbrugge O, Zielinski C, Pabinger I, Ay C. Treatment of venous thromboembolism in patients with cancer: A network meta-analysis comparing efficacy and safety of anticoagulants. Thromb Res. 2015 Sep;136(3):582–9.

146. Kahale LA, Hakoum MB, Tsolakian IG, Matar CF, Terrenato I, Sperati F, et al. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer. Cochrane database Syst Rev. 2018 Jun;6:CD006650.

147. Li A, Garcia DA, Lyman GH, Carrier M. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis. Thromb Res. 2019 Jan;173:158–63.

148. Bassand J-P, Accetta G, Al Mahmeed W, Corbalan R, Eikelboom J, Fitzmaurice DA, et al. Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation. PLoS One. 2018;13(1):e0191592.

149. Shen AY-J, Yao JF, Brar SS, Jorgensen MB, Chen W. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol. 2007 Jul;50(4):309–15.

150. Klatsky AL, Friedman GD, Sidney S, Kipp H, Kubo A, Armstrong MA. Risk of hemorrhagic stroke in Asian American ethnic groups. Neuroepidemiology. 2005;25(1):26–31.

151. Ayala C, Greenlund KJ, Croft JB, Keenan NL, Donehoo RS, Giles WH, et al. Racial/ethnic disparities in mortality by stroke subtype in the United States, 1995-1998. Am J Epidemiol. 2001 Dec;154(11):1057–63.

152. Yamashita Y, Morimoto T, Toyota T, Shiomi H, Makiyama T, Ono K, et al. Asian patients versus non-Asian patients in the efficacy and safety of direct oral anticoagulants relative to vitamin K antagonist for venous thromboembolism: A systemic review and meta-analysis. Thromb Res. 2018 Jun;166:37–42.

153. Patel JP, Roberts LN, Arya R. Anticoagulating obese patients in the modern era. Br J Haematol. 2011 Oct;155(2):137–49.

154. Zhou Y, Ma J, Zhu W. Efficacy and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation Across BMI Categories: A Systematic Review and Meta-Analysis. Am J Cardiovasc Drugs. 2019 Jul;

155. Boonyawat K, Caron F, Li A, Chai-Adisaksopha C, Lim W, Iorio A, et al. Association of body weight with efficacy and safety outcomes in phase III randomized controlled trials of direct oral anticoagulants: a systematic review and meta-analysis. J Thromb Haemost. 2017 Jul;15(7):1322–33.

156. Proietti M, Guiducci E, Cheli P, Lip GYH. Is There an Obesity Paradox for Outcomes in Atrial Fibrillation? A Systematic Review and Meta-Analysis of Non-Vitamin K Antagonist Oral Anticoagulant Trials. Stroke. 2017 Apr;48(4):857–66.

157. Tittl L, Endig S, Marten S, Reitter A, Beyer-Westendorf I, Beyer-Westendorf J. Impact of BMI on clinical outcomes of NOAC therapy in daily care - Results of the prospective Dresden NOAC Registry (NCT01588119). Int J Cardiol. 2018 Jul;262:85–91.

158. Hart R, Veenstra DL, Boudreau DM, Roth JA. Impact of Body Mass Index and Genetics on Warfarin Major Bleeding Outcomes in a Community Setting. Am J Med. 2017 Feb;130(2):222–8.

159. Oden A, Fahlen M, Odén A, Fahlén M, Oden A, Fahlen M. Oral anticoagulation and risk of death: A medical record linkage study. Br Med J. 2002 Nov;325(7372):1073–5.

160. Berwaerts J, Dijkhuizen RS, Robb OJ, Webster J. Prediction of functional outcome and in-hospital mortality after admission with oral anticoagulant-related intracerebral hemorrhage. Stroke. 2000 Nov;31(11):2558–62.

161. Sanden P, Renlund H, Svensson PJ, Sjalander A. Bleeding complications and mortality in warfarin-treated VTE patients, dependence of INR variability and iTTR. Thromb Haemost. 2017 Jan;117(1):27–32.

162. Bjorck F, Renlund H, Lip GYH, Wester P, Svensson PJ, Sjalander A. Outcomes in a Warfarin-Treated Population With Atrial Fibrillation. JAMA Cardiol. 2016 May;1(2):172–80.

163. Rivera-Caravaca JM, Roldan V, Esteve-Pastor MA, Valdes M, Vicente V, Lip GYH, et al. Importance of time in therapeutic range on bleeding risk prediction using clinical risk scores in patients with atrial fibrillation. Sci Rep. 2017 Sep;7(1):12066.

164. Van Den Ham HA, Klungel OH, Leufkens HGM, Van Staa TP. The patterns of anticoagulation control and the risk of stroke, bleeding and mortality in patients with non-valvular atrial fibrillation. J Thromb Haemost. 2013 Jan;11(1):107–15.

165. Hylek EM. Vitamin K antagonists and time in the therapeutic range: implications, challenges, and strategies for improvement. J Thromb Thrombolysis. 2013 Apr;35(3):333–5.

166. Rohla M, Weiss TW, Pecen L, Patti G, Siller-Matula JM, Schnabel RB, et al. Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF). BMJ Open. 2019 Mar;9(3):e022478.

167. Sakuma I, Uchiyama S, Atarashi H, Inoue H, Kitazono T, Yamashita T, et al. Clinical risk factors of stroke and major bleeding in patients with non-valvular atrial fibrillation under rivaroxaban: the EXPAND Study sub-analysis. Heart Vessels. 2019 May;

168. Westenbrink BD, Alings M, Connolly SJ, Eikelboom J, Ezekowitz MD, Oldgren J, et al. Anemia predicts thromboembolic events, bleeding complications and mortality in patients with atrial fibrillation: insights from the RE-LY trial. J Thromb Haemost. 2015 May;13(5):699–707.

169. Weiss HJ, Lages B, Hoffmann T, Turitto VT. Correction of the platelet adhesion defect in delta-storage pool deficiency at elevated hematocrit--possible role of adenosine diphosphate. Blood. 1996 May;87(10):4214–22.

170. Hijazi Z, Aulin J, Andersson U, Alexander JH, Gersh B, Granger CB, et al. Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation. Heart. 2016 Apr;102(7):508–17.

171. Takahashi H, Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet. 2001;40(8):587–603.

172. Lindh JD, Holm L, Andersson ML, Rane A. Influence of CYP2C9 genotype on warfarin dose requirements--a systematic review and meta-analysis. Eur J Clin Pharmacol. 2009 Apr;65(4):365–75.

173. Killu AM, Granger CB, Gersh BJ. Risk stratification for stroke in atrial fibrillation: a critique. Eur Heart J. 2019 Apr;40(16):1294–302.

174. Chao T-F, Lip GYH, Lin Y-J, Chang S-L, Lo L-W, Hu Y-F, et al. Incident Risk Factors and Major Bleeding in Patients with Atrial Fibrillation Treated with Oral Anticoagulants: A Comparison of Baseline, Follow-up and Delta HAS-BLED Scores with an Approach Focused on Modifiable Bleeding Risk Factors. Thromb Haemost. 2018 Apr;118(4):768–77.

175. Yoon M, Yang P-S, Jang E, Yu HT, Kim T-H, Uhm J-S, et al. Dynamic Changes of CHA2DS2-VASc Score and the Risk of Ischaemic Stroke in Asian Patients with Atrial Fibrillation: A Nationwide Cohort Study. Thromb Haemost. 2018 Jul;118(7):1296–304.

176. Chao T-F, Lip GYH, Liu C-J, Lin Y-J, Chang S-L, Lo L-W, et al. Relationship of Aging and Incident Comorbidities to Stroke Risk in Patients With Atrial Fibrillation. J Am Coll Cardiol. 2018 Jan;71(2):122–32.

177. Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol. 2011 Jul;58(4):395–401.

178. Gage BF, Yan Y, Milligan PE, Waterman AD, Culverhouse R, Rich MW, et al. Clinical classification schemes for predicting hemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006 Mar;151(3):713–9.

# Figure Legend

1. Central illustration of risk factors associated with stroke in AF

AF, atrial fibrillation; eGFR, estimated glomerular filtration rate; IL-6, interleukin-6; LA, left atrial; LAA, left atrial appendage; LV, left ventricle; MMP-2, matrix metalloproteinase-2; NOX2, reduced nicotinamide adenine dinucleotide phosphate oxidase 2; sCD40L, soluble CD40 ligand; SR, sinus rhythm; TE, thromboembolism; TIA, transient ischaemic attack; tPA, tissue plasminogen activator; vWF, von Willebrand factor.

\* Dashed lines indicate possible risk factors and the size of individual shapes reflect the degree of risk (Created with BioRender)

# Tables

1. Risk factors for stroke in AF

|  |  |  |
| --- | --- | --- |
|  | Risk factor | Possible risk factor |
| Clinical markers | Prior stroke, TIA or TEVascular disease+Increasing ageCongestive heart failureHypertensionDiabetes mellitusFemale sex\* |  |
|  Electrical markers | AF burdenCardioversion to SRAF type | AF morphology |
| Biological markers |
| *Blood markers* | Troponins I and TBNP and NT-proBNPReduced eGFRD-dimerInterleukin-6 | von Willebrand factorMean platelet volumeMMP-2NOX2-derived peptideSoluble CD40 ligandTumour necrosis factor-αtPAβ-thromboglobulin |
| *Urine markers* |  | AlbuminuriaProstaglandin F2α11-dehydro-thromboxane B2 |
| *Imaging markers* | LAA thrombiLA spontaneous echo contrastLAA flow velocityLAA morphologyLV dysfunctionLA enlargement | LA fibrosisLAA dimensionsComplex aortic plaque |
| Genetic marker | Genetic variants on chromosome 4q25 | FGB 455 G/A polymorphism~ |

AF, atrial fibrillation; BNP, B-type natriuretic peptide; eGFR, estimated glomerular filtration rate; LA, left atrial; LAA, left atrial appendage; LV, left ventricle; MMP-2, matrix metalloproteinase-2; NOX2, reduced nicotinamide adenine dinucleotide phosphate oxidase 2; NT-proBNP, N-terminal pro-B-type natriuretic peptide; SR, sinus rhythm; TE, thromboembolism; TIA, transient ischaemic attack; tPA, tissue plasminogen activator.

\* Risk modifier

+ Includes prior myocardial infarction, peripheral artery disease, or aortic plaque

1. Electrical markers relating to AF and stroke risk

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Study, year (ref) | Design | Study population | n | % male; mean (SD) or median (IQR) age, years | Relevant outcome measures | Follow-up duration | Electrical marker | Findings |
| Chu, 2019 (45) | Retrospective cohort | Undergoing pacemaker implantation | 152 | 56.4;73.2 (13.3) | Ischaemic stroke, TIA or SE | 67 months | AF burden | Higher AF burden was associated with greater risk of ischaemic stroke, TIA or SE |
| Go, 2018 (44) | Retrospective cohort | AF on 14-day ambulatory ECG monitoring | 1,965 | 55.2;68.8 (11.8) | Ischaemic stroke and SE | NA (retrospective) | AF burden | Higher AF burden was associated with greater risk of ischaemic stroke or SE |
| Link, 2017 (39) | Sub-analysis of RCT | AF with at least 2 stroke risk factors | 21,105 | 61.9;70.6 (NA) | Stroke or SE | 2.8 years | AF type | Paroxysmal AF was associated with lower risk of stroke or SE compared to persistent and permanent AF |
| Boriani, 2014 (43) | Pooled analysis of 5 prospective studies | Pacemaker or ICD *in situ* | 10,016 | 69;70 (61 - 76) | Ischaemic stroke | 24 months | AF burden | Higher AF burden was associated with greater risk of ischaemic stroke |
| Healey, 2012 (41) | RCT | Aged ≥65 years, known HTN and recent pacemaker or ICD implanatation | 2,580 | 58.4;76.1 (NA) | Ischaemic stroke or SE | 2.5 years | AHRE (>190 bpm for >6 minutes) | Presence of AHREs were associated with a 5.6-fold greater risk of ischaemic stroke or SE |
| Friberg, 2010 (34) | Retrospective cohort | AF (or atrial flutter) | 1,981 | NA;75.8 (NA) | Ischaemic stroke | 3.6 years | AF type | No association with ischaemic stroke |
| Yilmaz, 2007 (50) | Retrospective cohort | AF lasting longer than 24 hours | 811 | 45.9;60 (13) | History of stroke or TIA | NA (retrospective) | Coarse or fine AF | Coarse AF was associated with greater risk of stroke or TIA |
| Hohnloser, 2007 (36) | RCT | AF with at least 1 stroke risk factor | 6,706 | 66;70.2 (NA) | Stroke or SE  | 1.3 years | AF type | No association with stroke or SE |
| Capucci, 2005 (42) | Prospective cohort | Indication for pacemaker and history of symptomatic atrial tachyarrhythmias | 725 | 49.7;71 (11) | Ischaemic stroke, TIA or SE | 22 months | AF duration | AF duration longer than 24 hours was associated with greater risk of ischaemic stroke, TIA or SE |
| Glotzer, 2003 (40) | RCT | SND undergoing pacemaker implantation | 312 | 45;74 (NA) | Death of non-fatal stroke | 33.1 months | AHRE (>220 bpm for 10 consecutive beats) | Presence of AHREs were associated with greater risk of composite endpoint |
| Hart, 2000 (35) | Prospective cohort | AF | 2,012 | 71.5;69.1 (NA) | Ischaemic stroke | 2 years | AF type | No association with ischaemic stroke  |

AF, atrial fibrillation; AHRE, atrial high rate episode; ECG, electrocardiogram; HTN, hypertension; ICD, implantable cardioverter defibrillator; IQR, interquartile range; NA, not applicable or available; RCT, randomised controlled trial; SD, standard deviation; SE, systemic embolism; SND, sinus node disease; TIA, transient ischaemic attack.

1. Blood-based biomarkers for stroke risk in AF

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Study, year (ref) | Design | Study population | n | % male; mean (SD) or median (IQR) age, years | Relevant outcome measures | Follow-up duration | Biomarker | Findings |
| Park, 2019 (90) | Prospective registry | AF | 10,978 | 63.6;73.5 (11.8) | Stroke | 42.6 months | Platelet count (<100 x 109/L) | Lower platelet counts were associated with lower risk of stroke |
| Janion-Sadowska, 2018 (89) | Prospective cohort | AF on NOAC | 124 | 33.1; 70.3 (NA) | Stroke or TIA | 55 months | Platelet count (<100 x 109/L) | No association with stroke or TIA |
| Rivera-Caravaca, 2018 (103) | Prospective cohort | AF on OAC, attending clinic | 1,226 | 49.7; 76 (70 - 81) | Ischaemic stroke | 6.5 years | Soluble fibrin monomer complex | No association with ischaemic stroke |
| You, 2018 (88) | Case-controlled study | Non-anticoagulated AF | 323 | 63.8;75.2 (NA) | Ischaemic stroke | NA(retrospective) | D-dimer | No association with ischaemic stroke |
| Ancedy, 2018 (94) | Prospective cohort | Hospitalised AF | 122 | 46;70 (14) | Composite of all-cause death and stroke; stroke | 5 years | vWF | Higher vWF levels were associated with greater risk of composite endpointNo association with stroke risk only |
| Hayashi, 2018 (59) | Prospective registry | AF | 1,013 | 71.6;72.8 (9.7) | Stroke, TIA or SE | 25 months | BNP | High BNP levels were associated with a 3.9-fold greater risk of stroke, TIA or SE |
| Choi, 2017 (99) | Prospective cohort | AF | 352 | 57.4;68.4 (12.1) | Composite of ischaemic stroke and incidental LA thrombus | 35.4 months | Antithrombin III | No association with composite endpoint |
| MPV | High MPV levels were associated with a 6.4-fold greater risk of composite endpoint |
| Aulin, 2015 (96) | Sub-study of RCT | AF with at least 1 stroke risk factor | 6,187 | 63.7;72 (67 - 77) | Stroke or SE | 2 years | IL-6 | Higher IL-6 levels were associated with greater risk of stroke or SE |
|  |  | CRP | No association with stroke or SE |
|  |  | Fibrinogen | No association with stroke or SE |
| Pignatelli, 2015 (100) | Prospective cohort | AF | 950 | 55.5;73.3 (8.8) | Composite of stroke, TIA, MI and coronary revascularization | 25.7 months | Serum NOX2-derived peptide | Higher serum NOX2-derived peptide levels were associated with greater risk of composite endpoint |
| Banerjee, 2014 (66) | Prospective cohort | AF | 5,912 | 62.9;70.9 (NA) | Ischaemic stroke or TE | 2.5 years | eGFR (MDRD) | Lower levels of renal function were associated with greater risk of ischaemic stroke or TE |
| Roldan, 2014 (58) | Prospective cohort | AF on OAC, attending clinic | 1,172 | 49;76 (71 - 81) | Stroke or TIA | 34 months | NT-proBNP | High NT-proBNP levels were associated with a 2.7-fold greater stroke or TIA risk |
| Apostolakis, 2013 (67) | Post-hoc analysis of RCT | AF | 4,576 | 66.5;70 (9) | Stroke or SE | 10.8 months | CrCl, eGFR (MDRD, CKD-EPI) | Lower levels of renal function were associated with greater risk of stroke or SE |
| Krishnamoorthy, 2013 (93) | Prospective cohort | AF, attending clinic | 423 | 55.6;72.7 (8.4) | Composite of stroke, acute MI and all-cause mortality; ischaemic stroke | 19 months | vWF | Higher vWF levels were associated with greater risk of composite endpoint and ischaemic stroke |
|  |  | Soluble E-selectin | Higher soluble E-selectin levels were associated with greater risk of composite endpoint and ischaemic stroke |
| Hijazi, 2013 (57) | Sub-study of RCT | AF with at least 1 CHADS2 risk factor | 14,892 | 64.4;NA | Stroke or SE | 1.9 years | NT-proBNP | Higher NT-proBNP levels were associated with greater risk of stroke or SEHighest quartile of NT-proBNP was associated with 2.4-fold greater risk of stroke or SE compared to lowest quartile |
| Piccini, 2013 (17)  | Sub-study of RCT | AF with at least 1 stroke risk factor | 14,264 | 60.7;73 (NA) | Stroke or SE | 1.9 years | CrCl, eGFR (MDRD) | Lower levels of renal function were associated with greater risk of stroke or SE; every 10-mL/min decrease in CrCl resulted in 1.12-fold increase in risk; every 5mL/min/1.73 m2 decrease in eGFR (MDRD) resulted in 1.09-fold increase in risk |
| Hijazi, 2012 (56) | Sub-study of RCT | AF with at least 1 stroke risk factor | 6,189 | 63.7;72 (67 - 77) | Stroke | 2.2 years | NT-proBNP | Higher NT-proBNP levels were associated with greater stroke riskHighest quartile of NT-proBNP was associated with 2.4-fold greater risk of stroke compared to lowest quartile |
|  |  | Troponin I | Higher troponin I levels were associated with greater stroke riskHighest quartile of troponin I was associated with 2.0-fold greater risk of stroke compared to lowest quartile |
| Roldan, 2012 (55) | Prospective cohort | AF on OAC, attending clinic | 930 | 51;76 (70 - 81) | Stroke or TIA | 2 years | Troponin T | High troponin T levels were associated with a 2.4-fold greater stroke or TIA risk |
|  |  | IL-6 | No association with stroke or TIA |
| Ehrlich, 2011 (97) | Prospective cohort | AF | 278 | 63;70 (11) | Composite of stroke, MI, SE and all-cause death | 28 months | hsCRP | No association with composite endpoint |
| sCD40L | No association with composite endpoint |
|  | MMP-2 | Higher MMP-2 levels were associated with greater risk of composite endpoint |
|  | vWF | No association with composite endpoint |
|  | sVCAM-1 | Higher sVCAM-1 levels were associated with greater risk of composite endpoint |
| Roldan, 2011 (92) | Prospective cohort | AF on OAC, attending clinic | 829 | 50;76 (70 - 80) | Composite of TE, acute MI and acute HF | 27.6 months | vWF | High vWF levels were associated with a greater risk of composite endpoint |
| Ha, 2011 (101) | Prospective cohort | AF | 200 | 56;68.9 (11.7) | Ischaemic stroke | 15.1 months | MPV | Higher MPV levels were associated with greater ischaemic stroke riskHighest tertile of MPV was associated with a 5.0-fold greater risk of ischaemic stroke compared to lowest quartile |
| Sadanaga, 2011 (54) | Post-hoc analysis of prospective cohort | AF on OAC | 261 | 56;74 (9) | Ischaemic stroke, TIA or SE | 24.7 months | BNP | High BNP levels were associated with a 5.3-fold greater risk of ischaemic stroke, TIA or SE |
| Sadanaga, 2010 (87) | Prospective cohort | AF on OAC | 269 | 57;74 (9) | Ischaemic stroke, TIA or SE | 25.2 months | D-dimer | High D-dimer levels were associated with a 15.8-fold greater risk of ischaemic stroke, TIA or SE |
| Go, 2009 (68) | Sub-study of prospective cohort | AF | 10,908 | 57.2;71.6 (NA) | TE | 3 years | eGFR (MDRD) | Lower levels of renal function were associated with greater TE risk |
| Pinto, 2009 (91) | Prospective cohort | Chronic AF | 373 | 63.5;66.1 (7.4) | Ischaemic stroke | 3 years | IL-1β | No association with ischaemic stroke |
| TNF-α | Higher TNF-α levels were associated with greater ischaemic stroke risk |
| IL-6 | Higher IL-6 levels were associated with greater ischaemic stroke risk |
|  | IL-10 | No association with ischaemic stroke |
|  | E-selectin | No association with ischaemic stroke |
|  | P-selectin | No association with ischaemic stroke |
|  | ICAM-1 | No association with ischaemic stroke |
|  | VCAM-1 | No association with ischaemic stroke |
|  | vWF | Higher vWF levels were associated with greater ischaemic stroke risk |
| Ferro, 2007 (102) | Prospective cohort | AF | 231 | 48;72.4 (10.3) | Composite of stroke and MI | 27.8 months | sCD40L | High sCD40L levels were associated with a 4.6-fold greater risk of composite endpoint |
| Nozawa, 2006 (85) | Prospective cohort | AF | 509 | 64.8;66.6 (10.3) | Composite of clinically evident stroke, TIA and SE | 2 years | D-dimer | High D-dimer levels were associated with a greater risk of composite endpoint |
|  | F1+2 | No association with composite endpoint |
|  | Platelet factor 4 | No association with composite endpoint |
|  | β-thromboglobulin | No association with composite endpoint |
| Conway, 2004 (95) | Prospective cohort | AF, attending clinic | 77 | 57;68 (62 - 75) | Stroke | 6.3 years | IL-6 | High IL-6 levels were associated with a 2.9-fold greater stroke risk |
|  | CRP | No association with stroke |
| Vene, 2003 (86) | Prospective cohort | AF referred to clinic for initiation of OAC | 113 | 60;70.2 (5.4) | Composite of stroke, MI, SE, peripheral vascular occlusion and cardiovascular death | 44.3 months | D-dimer | Higher D-dimer levels were associated with greater risk of composite endpoint |
|  |  | tPA | Higher tPA levels were associated with greater risk of composite endpoint |
|  |  | F1+2 | No association with composite endpoint |
|  |  | TAT complexes | No association with composite endpoint |
|  |  | PAI-1 | No association with composite endpoint |
| Feinberg, 1999 (98) | Sub-study of prospective cohort | AF with at least 1 high-risk stroke factor | 1,531 | NA;70 (NA) | Ischaemic stroke or SE | 2 years | F1+2 | No association with ischaemic stroke or SE |
| β-thromboglobulin | No association with ischaemic stroke or SE |
| Fibrinogen | No association with ischaemic stroke or SE |
|  | Factor V Leiden mutation | No association with ischaemic stroke or SE |

AF, atrial fibrillation; BNP, B-type natriuretic peptide; CrCl, creatinine clearance; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; F1+2, prothrombin fragment F1+2; hsCRP, high-sensitivity C-reactive protein; ICAM-1, intercellular adhesion molecule-1; IL-10, interleukin-10; IL-1β, interleukin-1β; IL-6, interleukin-6; IQR, interquartile range; LA, left atrial; MDRD, Modification of Diet in Renal Disease Study; MI, myocardial infarction; MMP-2, matrix metalloproteinase-2; MPV, mean platelet volume; NA, not applicable or available; NOAC, non-vitamin K oral anticoagulants; NOX2, reduced nicotinamide adenine dinucleotide phosphate oxidase 2; NT-proBNP, N-terminal pro-B-type natriuretic peptide; OAC, oral anticoagulation; PAI-1, plasminogen activator inhibitor-1; RCT, randomised controlled trial; sCD40L, soluble CD40 ligand; SD, standard deviation; SE, systemic embolism; sVCAM-1, soluble vascular cell adhesion molecule-1; TAT, thrombin-antithrombin; TE, thromboembolism; TIA, transient ischaemic attack; TNF-α, tumour necrosis factor-alpha; tPA, tissue plasminogen activator; vWF, von Willebrand factor.

1. Structural biomarkers for stroke risk in AF

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Study, year (ref) | Design | Study population | n | % male; mean (SD) age, years | Relevant outcome measures | Follow-up duration | Biomarker | Findings |
| Dakay, 2018 (109) | Prospective cohort | AF hospitalised with ischaemic stroke | 225 | 44.4;79.5 (10.5) | Anticoagulation failure | NA | LAE | More severe left atrial enlargement was associated with greater risk of anticoagulation failure resulting in stroke |
| Hamatani, 2016 (108) | Prospective registry | AF | 2,713 | 60.2;73.7 (NA) | Ischaemic stroke or SE | 32.6 months | LAE | LA diameter >45mm was associated with a 1.7-fold greater risk of ischaemic stroke or SE |
| Kong, 2014 (115) | Prospective cohort | Drug-refractory AF undergoing catheter ablation | 219 | 65.3;58.1 (NA) | Stroke | NA(retrospective) | LAA morphology | Non-chicken wing morphology was associated with 5.8-fold greater stroke risk |
| Khurram, 2013 (117) | Prospective cohort | AF referred for catheter ablation | 678 | 74.8;59.5 (9.7) | Stroke or TIA | NA(retrospective) | LAA morphology | No association with stroke or TIA |
| LAA trabeculations | Extensive LAA trabeculation was associated with a greater stroke or TIA risk |
| LAA orifice diameter | Smaller LAA orifice was associated with a greater stroke or TIA risk |
| LAA length | Shorter LAA length was associated with a greater stroke or TIA risk |
| Kimura, 2013 (116) | Case-controlled study | Drug-refractory AF who underwent catheter ablation | 80 | 82.5;58.6 (6.0) | Stroke | NA(retrospective) | LAA morphology | Cauliflower morphology was associated with a greater stroke risk |
| Di Biase, 2012 (114) | Prospective cohort | Drug-refractory AF undergoing catheter ablation | 932 | 79;59 (10) | Ischaemic stroke or TIA | NA(retrospective) | LAA morphology | Chicken wing morphology was associated with lowest risk of ischaemic stroke or TIA; with chicken wing morphology as reference, cactus, windsock and cauliflower were associated with a 4.1-fold, 4.5-fold and 8.0-fold greater risks of ischaemic stroke or TIA, respectively |
| Beinart, 2011 (118) | Case-controlled study | Non-anticoagulated AF  | 144 | 75;54.5 (9.9) | Stroke or TIA | NA(retrospective) | LAA volume | No association with stroke or TIA |
| LAA depth | No association with stroke or TIA |
| LAA neck dimensions | High LAA neck dimension was associated with greater stroke or TIA risk |
| LAA number of lobes | No association with stroke or TIA |
| Goldman, 1999 (111) | Sub-study of prospective cohort | AF with at least 1 high-risk stroke factor\* | 721 | 76;68 (9) | Ischaemic stroke or SE | NA | LAA peak antegrade flow velocity | LAA peak antegrade flow velocity <20 cm/s was associated with greater risk of ischaemic stroke or SE |
| Zabalgoitia, 1998 (113) | Sub-study of prospective cohort | AF with at least 1 high-risk stroke factor\* | 786 | 76;69 (9) | Ischaemic stroke or SE | NA | LAA thrombus | Presence of LAA thrombus was associated with a 2.5-fold greater risk of ischaemic stroke or SE |
|  | SEC | Presence of SEC was associated with a 3.7-fold greater risk of ischaemic stroke or SE |
|  | LAA peak antegrade flow velocity | LAA peak antegrade flow velocity <20 cm/s was associated with a 1.7-fold greater risk of ischaemic stroke or SE |
|  | Complex aortic plaque | Presence of complex aortic plaque was associated with a 2.1-fold greater risk of ischaemic stroke or SE |
| Leung, 1994 (112) | Prospective cohort | AF undergoing TOE | 272 | 68;68 (11) | Stroke or SE | 17.5 months | LA SEC | Presence of LA SEC was associated with a 3.5-fold greater risk of stroke or SE |
| SPAF, 1992 (107) | Sub-study of RCT | AF | 568 | 70;67 (12) | Ischaemic stroke or SE | 1.3 years | 14 echocardiographic parameters | LV dysfunction and higher LA size were the associated with greater risk of ischaemic stroke or SE |

AF, atrial fibrillation; IQR, interquartile range; LA, left atrial; LAA, left atrial appendage; LAE, left atrial enlargement; LV, left ventricular; NA, not applicable or available; RCT, randomised controlled trial; SD, standard deviation; SE, systemic embolism; SEC, spontaneous echo contrast; TIA, transient ischaemic attack; TOE, trans-oesophageal echocardiography.

\* Similar study cohort

1. Risk factors for anticoagulation-related bleeding

|  |  |  |
| --- | --- | --- |
|  | Risk factor | Possible risk factor |
| Clinical markers | History of bleedingAntiplatelets or NSAID useExcess alcoholUncontrolled hypertensionIncreasing ageMalignancyPrior strokeVascular diseaseRace/ethnicity (non-white)Choice of anticoagulant | Diabetes mellitusFemale sexPrior fallsThyroid diseasePrior MI or known IHD |
| Biological markers | Poor anticoagulation control(high INR or reduced TTR)Liver dysfunctionRenal dysfunctionAnaemiaReduced platelet count or function | Interleukin-6von Willebrand factorGrowth differentiation factor-15Troponins |
| Genetic marker | CYP 2C9 polymorphism |  |

CYP, cytochrome P450; IHD, ischaemic heart disease; INR, international normalised ratio; MI, myocardial infarction; NSAID, non-steroidal anti-inflammatory drug; TTR, time-in-therapeutic range.

1. Bleeding risk scores in AF

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Risk factors | ABC-bleeding (134) | ATRIA bleeding (177) | HAS-BLED (18) | HEMORR₂HAGES (178) | ORBIT (178) |
| Antiplatelets or NSAID use |  |  | x |  | x |
| Diabetes mellitus |  |  |  |  |  |
| Excess alcohol |  |  | x | x |  |
| Excessive falls risk |  |  |  | x |  |
| Females |  |  |  |  | x |
| History of bleeding | x | x | x | x | x |
| Hypertension |  | x | x | x |  |
| Elderly patients | x | x | x | x | x |
| Malignancy |  |  |  | x |  |
| Previous stroke |  |  | x | x |  |
| Abnormal liver function |  |  | x | x |  |
| Abnormal renal function |  | x | x | x | x |
| Anaemia | x | x |  | x | x |
| Labile INR (TTR <60%) |  |  | x |  |  |
| Raised GDF-15 | x |  |  |  |  |
| Raised hsTrop | x |  |  |  |  |
| Reduced platelet count or function |  |  |  | x |  |
| CYP 2C9 polymorphism |  |  |  | x |  |
| Total score | 45 | 10 | 9 | 12 | 7 |

CYP, cytochrome P450; GDF-15, growth differentiation factor-15; hsTrop, high-sensitivity troponin; INR, international normalised ratio; NSAID, non-steroidal anti-inflammatory drug; TTR, time-in-therapeutic range.